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ABSTRACT

The goal of this dissertation is to understand the immune responses generated

against cutaneous herpes simplex virus(HSV)infection, with an emphasis on the role of
gamma-interferon (IFN-y)in mediating protection against HSV. Further, novel

approaches to achieve optimal immune responses by DNA vaccination in the murine
HSV model is explored.

A T-cell mediated inflammatory response dominated by BFN-y appears to play the

essential role in viral clearance during cutaneous HSV infection. In accordance with this

hypothesis, this dissertation shows that following infection, IFN-y gene knock-out
(GKO)mice are more susceptible to the development of skin lesions than are wild-type
mice. However, following HSV immunization, GKO mice become solidly immune to

viral challenge. In addition, transferring T cells from immune GKO mice to nude mice
recipients renders them resistant to zosteriform lesions. These results indicate that

compensatory mechanisms are available to the body to effect immunity against viral
infections.

To test the principle that genetically engineered epitopes in a plasmid DNA can

efficiently induce specific immunity, a study on HSV-specific immune responses induced
by vaccinating mice with a plasmid DNA (pcMini)encoding cytotoxic T lymphocyte

(CTL), helper T and B cell epitopes from HSV is described in this dissertation. Following
immunizations with pcMini, mice developed epitope-specific CTLs comparable to the
iv

responses induced by live HSV. Antibody,lymphoproliferative responses, and T cell
cytokine release were also detected. The protection provided by minigene vaccination
was significant; however, not as efficient as live virus immunization. The DNA minigene

approach may prove useful to define and induce immune responses against minimal
antigenic determinants.

To address the question of whether immune responses to a vector-encoded antigen
can be enhanced by the activation of antigen-presenting cells in the local environment,
the effects of co-inoculation of an HSV glycoprotein (gB)-expressing plasmid with a

plasmid encoding mouse granulocyte-macrophage colony-stimulatory factor(GM-CSF)
on modulation of gB-specific immune responses are evaluated in this dissertation. The
results show that co-administration of GM-CSF DNA provided increased resistance to

HSV infection and this protective response could be related to the enhanced immune
induction of CD4-t- T cells and B cells responses.
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Part I

A Review of The Literature

Introduction

Host defense mechanisms against viral infection are mediated by many

components. From innate to acquired defenses, from humoral to cellular responses,from
local to systemic reactions, each of these component must play its own role in the battle
against pathogens, while functioning as a part of a complex characterized by redundancy
and pleotropism. Understanding such complicated biologic systems has been an
formidable task for students of the life sciences, especially for immunologists. One

branch of this field, the investigation of immune responses to herpes simplex virus

(HSV), has progressed rapidly. The role of components of the immune system like
antibodies, 004"", and CDS'" T cells have been well characterized in mediating protective

immunity and the immunopathological responses to HSV in the past several decades
200,203. More recently, studies have focused on the role of anti-viral cytokines,

particularly IFN-yin HSV infection

18. 58- 204. One such study, presented in this

dissertation, demonstrated the function of IFN-yin cutaneous HSV infection by using a

transgenic mouse model in which the IFN-y gene is disrupted.
The ultimate goal for understanding how the immune system works is to uncover

strategies to prevent or cure the diseases induced by various pathogens. One powerful
method is to develop effective vaccines. Like many traditional vaccines, immunization
with attenuated live HSV virus protected mice against lesion development and

encephalitis ^16. However,the potential of latency induced by live HSV

and the

immunosuppression associated with HSV infectionhave been arguments against the use
of a live or attenuated forms of the virus as a vaccine ^9. Tremendous efforts have been

put in searching for alternatives. A potential breakthrough is the recent finding that
plasmid DNA encoding viral antigens stimulates both humoral and cellular immune
responses in animals. The DNA or genetic vaccine has rapidly followed. This
dissertation presents two of these recent investigations on the evaluation and modulation
of protective immunity induced by HSV DNA vaccines in a mouse model.
The literature reviewed in the following sections focuses on immune responses

generated against HSV cutaneous infection, as well as the recent development of DNA
vaccines.

Immunity Against HSV cutaneous infection

HSV cutaneous infection

Pathogenesis of HSV infection begins with viral replication, neurotransportation,
latency, and reactivation. These events have been demonstrated in both animal models
and humans

The initiation of HSV infection occurs when virus particles contact

mucosal surfaces or skin abrasions. Subsequent viral replication at the inoculation site
results in infection of sensory nerve endings. Virions or nucleocapsids are then

transported to the associated ganglia by retrograde axonal flow at a rate of approximately
lOmm/hr

After transport, the virus replicates within the sensory ganglia for several

days, or enters into a latent state in the ganglia. Latency is broken following certain
signals such as stress for reactivation. Infectious virions then spread by antegrade
transportation along peripheral sensor}' nerves to other epithelial surfaces where they
produce vesicles 30. Fig 1-1* illustrates the scheme of HSV infection.
Zosteriform spread of HSV in animals was first observed in rabbits by Teague and

Goodpasture in 1923 214. xhe same phenomenon was also reproduced in mice 210.
Animals injected cutaneously in the midflank region with herpes simplex virus developed
an ipsilateral bandlike lesion several days later. These skin lesions resembled to the

eruption of shingles caused by varicella-zoster virus in humans. One distinguishing
characteristic of the flank inoculation model is that the zosteriform lesions have two

different components: the initial local replication vesicles, and the lesions remote from
the initial sites. This makes it an important animal model in the study of viral

pathogenesis and immune mechanisms during the course of active primary and
recrudescent HSV infections

Innate defense mechanisms

Restriction of HSV to the peripheral nervous system is manifested at an early

stage of the infection, 3-5 days after flank inoculation^!, jj^is suggests that innate defense
mechanisms are likely responsible, concordant with the lack of MHC involvement. Host

genetic background, cellular components such as natural killer cells, macrophages.
* All tables and figures may be found at the end of each part.

Langerhan's cells, and neutrophils, as well as inflammatory lymphokines have been
demonstrated to form the first line of host defense to the viral infection.

Genetic background

In animal models, the susceptibility to herpes simplex virus-1 infection is often
associated with the genetic background of the animal. Early observations by Carlos Lopez
in 1978 131 and 1980 132 indicated that the resistance of inbred mouse strains to HSV-1

was: AKR (H-2'') or A (H-2') < DBA (H-2'') < CBA (H-2'') or BALB/c (H-2'') < C3H (H-

2'') or C57BR (H-2'') < C57BL/6 (H-2'') or C57BL/Ks (H-2'') or C57BL/10 (H-2''). By
crossing resistant and susceptible mice of different genetic backgrounds, resistance was
determined to be dominant, but not linked to the H-2 loci. In humans and animals, HSV-1

often causes mucocutaneous infection, while HSV-2 induces genital diseases. Unlike the

susceptibility of HSV-2, which is influenced by X-linked loci 33.152^ the resistance
patterns of HSV-1 were less sex-related. To date, the gene(s) that determine the resistance
to herpes simplex virus are yet to be identified.

Natural killer(NK)cells

NK cells are large granular lymphocytes, which are capable of carrying both

functions of cytotoxicity and lymphokine secretion. The actions of NK cells are neither
MHC-restricted nor antigen specific, and are important in innate defense against viral

infections and tumors. During HSV infection, NK cells have been shown to limit viral

replication both in vitro and in vivo ^3.78,177
Unlike T and B lymphocytes, NK cells lack surface receptors for antigen, but do

express at least three distinct surface receptors capable of triggering cytolytic effector
function. The first is CD 16, an immunoglobulin Fc receptor that allows NK cells to

mediate antibody-dependent killing (ADCC)i23,220_ xhe second NK cell-triggering

receptor is CD2,a 50-55kDa cell surface molecule that binds the MHC-I moleculei37_
Activation of NK cells via CD 16 and CD2 both results in tyrosine phosphorylation of the

receptor associated ^ subunit, also a component of T cell receptor(TCR)complex. The
third NK cell surface receptor is identified as NKR-Pl,that binds to carbohydrates on the
target cell surface 21. The activation pathway of NKR-Pl has not been clarified;

however, it may involve interaction with oligosaccharide ligands'®- ^'4. in addition to
these "on" signal transducers for NK cell activation, a group of molecules that function

as "off signal transducers for NK cell activities also exist. These receptors include Ly49

and p58/70, both of which bind to MHC-I complexes expressed on target cells 35,103,157_
Accumulating evidence has shown that MHC-class I expression by target cells inhibits
NK cell mediated cytotoxicity

iso, 208 _

In 1991, Lopez et al. observed that human fibroblasts infected with HSV were

more susceptible to lysis by NK cells than uninfected fibroblasts. This leads them to

speculate that HSV early immediate genes might direct the target cells to become

susceptible 62. in 1995, Johnson et al demonstrated that ICP47 of HSV down regulated

MHC-I presentation on infected human fibroblasts

217,25i 7^0 ability of HSV to

down-regulate MHC-1 expression on infected cells is perhaps one of the better studied
evasion mechanisms since it serves to disarm cytotoxic CDS"^ T cells. However,these

infected target cells are more susceptible to NK cell killing, an important mechanism by
which the innate immune system eliminated viral infections.

NK cell cytotoxicity is mediated mainly by the release of perforin from

cytoplasmic granules220. Lymphokines such as tumor necrosis factor(TNF),interferon
(IFN), and interleukin 2(IL-2) secreted by activated NK cells also play important roles in
host defense mechanisms. These will be discussed in the following sections.

Macrophages and Dendritic Cells

Macrophages (Mt})) and dendritic Cells(DC)are tissue phagocytic cells. Both

express high levels of surface MHC-II molecules and other co-stimulatory molecules such
as members of B7 and ICAM familiesfollowing activation

Both of these cell types

are considered to be the major antigen presenting cells(APCs)in the bodyi^k

The importance of M<1)S in controlling virus infection has long been recognized in
experimental animal models. The most definitive evidence for the role of M(j)S in
resistance to HSV came from the studies by Johnson et al. and Morahan et al. Adoptive

transfer of Mcjis from HSV-1-infected or immuno-modulator-treated adult mice to young,

naive mice conferred protection against lethal HSV-1 challenge

'56. Further, depletion

of tissue M(t)s markedly decreases the resistance of mice to HSV infection '72 7^0 role

of DCs,particularly Langerhans cells (LCs), which are bone marrow-derived DCs from
the mononuclear phagocyte lineage, and resident within epithelial tissues, has been

investigated in HSV infections of the cornea and skin. These studies used kinetic
correlative, cell depletion, and adoptive cell transfer methodologies to investigate the

pathogenesis of HSV. Depletion of LCs from murine skin led to enhanced virulence
following footpad infection with a nonpathogenic HSV strain 206_ Depletion of epidermal
LCs by in vivo exposure of mice to UV light impaired the resistance of mice to
intracutaneous infection with HSV

Adoptive cell transfer studies have also shown a

role for LCs in resistance to cutaneous HSV infection. Intracutaneous transfer of spleen

cells, stimulated in vitro with epidermal LCs and UV-inactivated HSV,reduced the virus
titer in the skin and the formation of zosterifrom skin lesions in nude mice infected

intracutaneously with HSV 247_
The exact mechanisms by which M(t)S and DCs mediate viral resistance have not

been clearly determined. Resistance may be mediated by these cells alone via extrinsic
mechanisms such as inhibition of viral spread 82, cytotoxicity of virus-infected cells''2, or
inhibition of virus replication in permissive cells '0'. Alternatively, it may be mediated

by intrinsic mechanisms such as blocking HSV-1 replication '2, or in concert with other
cell populations or factors (such as cytokines and antibody).

Polymorphonuclear Cells(PMN)

HSV-infected cells produce factors chemotactic for PMNs 205. Early studies
indicated that PMNs could inhibit bovine HSV-1 replication and cause ADCC ^^2. More

recently, human PMNs were demonstrated to exhibit both intrinsic and extrinsic
resistance to HSV infection 225-227. jhe exact role of PMN-mediated anti-viral
mechanisms in vivo remains to be established.

Adaptive defense mechanisms

As a first line of defense, the innate immune responses' non-specific

inflammatory changes parallel a peak in viral replication. Specific host responses,

however, join the defensive effort in more effective and durable ways. In the mouse
model, delayed-type hypersensitivity responses can be identified within 4-6 days after
disease onset,followed by a cytotoxic T-lymphocytes(CTL)response, and appearance of

both immunoglobulin IgM- and IgG-specific antibodiesi^^,255 Development of specific

responses in humans is more delayed, approximately 7-10 days after infection ^23.

Antibody

Humoral responses to HSV are as classically described, in which IgM antibodies

appear transiently and are followed by IgG and IgA antibodies. Neutralizing and
antibody-dependent cellular cytotoxic antibodies generally appear 2 to 6 weeks after
infection and persist for the lifetime of the host 113.

Early investigations demonstrated that polyclonal and monoclonal antibodies
administered early in the course of primary HSV infection can limit the spread of virus to

the sensory ganglia 200. However, high titers of antibody and administration of antibody
within 48 hours of infection are conditions required to achieve this effect

Administration of physiological titers of antibodies failed to protect the animal, regardless
of when administered 54. Therefore, passive transfer of antibody does not mimic the
natural role of antibodies in controlling HSV infections in the nervous system.

B cell-suppressed mice have been used to determine whether endogenously

produced antibody contributes to the control of primary HSV 1^2. in the absence of an
antibody response, primary infection is quantitatively greater and more widespread.
However, elimination of antibodies has no effect on the resolution of cutaneous herpes,

and clearance of virus from the peripheral nervous system(PNS)is not delayed 201.

Kappour et al. also found that latent virus could be reactivated more frequently from the

ganglia of mice lacking B cell function during primary infection than from the ganglia of
normal animals. Therefore, it was concluded that antibody has a subtle and potentially

important role in reducing the number of neurons exposed to virus, but other mechanisms

are responsible for removal of infectious material. Perhaps the quality and rapidity of the
antibody response are factors which determine how far and wide the virus spreads.
The mechanism by which antibody prevents the spread of HSV in the peripheral

nervous system is unknown. One common hypothesis is that high titers of antibodies have

the capacity to reduce the spread of infection by neutralizing extracellular virus. This is
10

supported by many observations in which protection against viral challenge is readily
achieved by immunization with envelope glycoproteins, common neutralizing targets'^.
Among the seven glycoproteins associated with the vims envelope, glycoprotein D(gD)
is the dominant target for naturally occurring neutralizing antibodiesi^^.

Cytotoxic T lymphocytes(CTL)

Characterization of HSV-specific, MHC-restricted CTLs were first carried out in

mice

195 Analysis of primary CTL responses in vitro against HSV in mice revealed

weak cytolytic activities. One possible explanation was that suppressor cell activity
inhibits the expression of CTL activity in vivo. This has been supported by several
observations including those in which CTL responses are enhanced by impairing

suppressor cells with cyclophosphamide >25, and by in vitro demonstration of both
antigen-specific and nonspecific suppressor activity
inadequate levels of T cell help

Another theory focuses on

^29.

In contrast, HSV-specific memory cells can be readily stimulated in vitro with

vims to high levels of activity that is both antigen-specific and MHC-restricted

The

induction of a secondary in vitro response to HSV has been shown to require the

participation of adherent APCs, helper T cells, or their cytokine products 1^8,191,192,
Since T cells recognize only processed peptide in association with an MHC

molecule, any protein synthesized from a viral genome is a potential target antigen.
Recombinant DNA technology using vectors such as vaccinia, adenoviras, or baculovims
11

to express a variety of HSV proteins has been used primarily to define HSV target

antigens for CTLs. Many CTL epitopes have been identified in glycoproteins'^. 185^ and
some were found in internal proteins, such as ICPO,ICP4, and ICP27

219.

The role of CD8"^ T cells in controlling the progression of HSV infection in vivo

was studied by adoptive transfer experiments. Controversial results have been reported

from independent research groups. While Sethi and Larsen claimed that CD8"^ T cells
were exclusively responsible for protecting mice in adoptive transfer models 124,196^
others showed no contribution of CD8^ T cells in protection i^^. Perhaps CD8'^-mediated
host defense mechanisms are tissue-specific, and viral dose dependent. Recent studies

have shown that preventing viral invasion to the CNS is a major function of CD8"^ T
cells 202^ and 008"^ T cells are also required to clear high doses of virus from the skin and

prevent viral replication within the PNS 196.204.
Besides 008"" T cells which are MHC-I-restricted cytotoxic lymphocytes, MHC-II

restricted cytotoxic T cells (004"^) also play a role in many viral infections, including
HSV

ii'^-

2'^6

functions of these €04"^ CTLs in vivo are unknown. Some

suspect these cells destroy APCs, resulting in the down-regulation of ongoing

responses 169. Whether these €04"^ CTLs also play a role in elimination or control of
HSV infection has yet to be determined.

Classical understanding of the mechanisms of T cell-mediated cytotoxicity was

based on perforin, a molecule released from CTLs upon TCR engagement that induces
membrane destruction of the target cells 9.252. Perforin-deficient mice failed to clear
12

Lymphocytic Choriomeningitis virus in vivo, yet substantial killing activity was still
detected in vitro by CTL's from peforin free mice 134. Lowin et at. first reported that Fas

ligand, which binds to Fas, an apoptosis-signaling receptor molecule on the surface of a
number of different cells, also mediates the lytic activity of cytotoxic T cells 134. The T

cell receptor signaling requirements for perforin or FasL-mediated cytotoxicity are
distinct 35; however, the exact mechanisms involved remain elusive. It seems likely that a

family of cysteine proteases (Caspases) related to interleukin-ip converting enzyme(ICE)
are involved

T helper cells(Th)

T helper cells are responsible for releasing cytokines, mediating delayed T cell
hypersensitivity reactions(DTH),and facilitating B cell responses. The majority of these

helper cells are €04"^ T cells. Based on their cytokine production profile, CD4"'T cells
are subdivided into two categories. Type 1 cells(Thl) produce IFN-y,IL-2, and

lymphotoxin, but not IL-4. Type 2 cells(Th2)release IL-4,IL-5,IL-6,IL-9,IL-10 and IL13, but not IFN-y ^39. Several other proteins are secreted both by Thl and Th2 cells,
including IL-3, tumor necrosis factor a(TNFa), granulocyte-macrophage colony-

stimulating factor(GM-CSF),and proteins of the chemokine(CK)families

The

functions of Th cells correlate well with their distinctive cytokines. Thl cells are involved

in cell-mediated inflammatory reactions ^39, inducing DTH responses 222^ even providing

13

B cell help 27. Th2 cytokines are commonly found in association with strong antibody and
allergic responses^

27.

Marine studies have provided evidence that CD4''' T cells can protect against HSV

infection, especially in clearing low dose infections in the skin ^'^2,164 Adoptive transfer

of HSV-primed CD4"^ T cells alone to naive nude mice is sufficient to prevent zosteriform
viral challenge, demonstrated by Manickan et

This subset interestingly also

produces predominantly IFN-y.

The mechanisms of Th cell-mediated protection against HSV are most likely

associated with their cytokine production. In the following section, the activity of

cytokines which are involved in the host responses to HSV infection will be discussed.

Cvtokine mediated defense mechanisms

Cytokines are low molecular weight proteins secreted by leukocytes and a variety
of other cells in the body in response to stimuli. Interaction between a cytokine and its

receptor on the target cell surface triggers an altered pattern of gene expression in the
target cell. Signal delivery via cytokines provides opportunities for cell-to-cell
communication without direct physical contact between the cells. Cytokines also exhibit

the attributes of pleiotropy, redundancy, synergy, and antagonism, permitting them to

regulate cellular activities in a coordinated and interactive way. Upon HSV infection, a
number of cytokines are secreted by host cells including IFNs,IL-1, IL-6,IL-10,IL-12,

14

GM-CSF,and TNF-a

Studies on IFNs,TNF-a, and the recently described cytokine

IL-12, have demonstrated their immunomodulative activities against HSV infection.

IFNs

There are two types of IFNs. Type I are encoded by a family of genes, includes a,

p and CO. Type II, encoded by a different gene, includes IFN-y. The antiviral properties of
IFNs have been known for several decades. Early investigators used antibodies to IFN to
demonstrate its action in vivo ^7.75 Recent studies with transgenic mice with loss of IFNs

or their receptor genes also revealed the importance of IFNs in resistance to viral,
intracellular bacterial and parasitic infections 34,92, 162_ IFNs additionally regulate other
cellular activities, such as increasing cell surface expression of MHC molecules,

augmentation of M<t) activity, and recruitment and activation of NK cells.
The importance of the Type I IFNs in murine models of HSV infection was
demonstrated by a greatly reduced resistance to HSV-1 challenge following

administration of oc/p IFN-neutralizing immunoglobulin '^5. In human patients with
advanced stages of AIDS,there is deficient IFN-a production by peripheral blood
mononuclear cells(PBMC)in response to HSV infection

198_ xhis deficiency may be

related to the increased susceptibility of these individuals to severe infection by HSV.

Exogenous administration of IFN- oc/P has been shown to lessen the severity of

symptoms caused by HSV in human 126. The molecular basis for the antiviral activity of
IFN is not fully understood; however, in vitro evidence suggests that IFN-a interferes
15

with virion protein VP-16-niediated transactivation of HSV immediate early promoters,
thereby inhibiting viral replication^!.

iPN-y may exert its antiviral activities in vivo

through different and non-redundant pathways from the type I IFNs, based on responses
of Type I and Type IIIFN receptor knock-out mice to vesicular stomatitis virus
infection

IFN-y is exclusively produced by activated NK cells and T lymphocytes. Its role in
host defense against HSV is complicated because IFN-y regulates nearly every aspect of
the immune system. The functions of IFN-y include activation of Mtj), up-regulation of
class I and class IIMHC expression, induction of antibody class switching to IgG2a,
inhibition of the IL-4-induced class switch to IgE and IgGl, and mediation of various

components important in DTK and cytotoxicity 7.34. Using neutralizing mAb to IFN-y
and adoptive transfer of T cell subsets, Jennings et al. revealed that protection against
acute cutaneous HSV infection is controlled by IFN-y, independent of CD4"^ and CDS"^ T
cells 204. The studies presented in this dissertation investigate the role of IFN-y in HSV
infection using a transgenic mouse model,GKO mice, lacking IFN-y gene expression.
The resistance to HSV-1 zosteriform challenge is reduced in GKO mice compared to

wildtype controls. However, using less a virulent vims to immunize GKO mice, there is
induciton of solid immunity to HSV.These results suggested that EFN-y plays a more

important role during the effector phase of controlling viral infection than during the
immune induction phase.

16

TNF-a

TNFa is synthesized by macrophages and other cells. In vitro infection of human

peripheral blood mononuclear cells(PBMCs)with HSV-1 induces TNFa production 74,
which also persists in trigeminal ganglia latently infected with HSV-1 80. The role of
TNF-a in the inhibition of HSV pathogenesis is related to IFN-y. Evidence provided by

several research groups has shown that TNF-a synergizes with the interferons in the
blockade of HSV-1 replication both in vivo and in vitro 23.52,59 Using anti-TNF-a
neutralizing antibodies to deplete TNF-a in severe combined immunodeficiency (SCID)
mice resulted in a reduction of peritoneal M(t) infiltration and an increase in the viral titers
in the liver and spleen, supporting the important role of innate immunity in HSV
infections.

The mechanisms of the antiviral activity of TNF-a have been studied in several

laboratories. A report from the Lidbury and Cowden et at. indicated that neither reactive

nitrogen intermediates nor arachidonic acid metabolites are involved in the antiviral
mechanisms of TNF-a. However, reactive oxygen intermediates and free radicals may

play an important role 127. a recent study by Spear et al. has shown that entry of HSV
into host cells is mediated by a cellular mediator from the TNF/NGF(neuron growth

factor) receptor family. TNF-a,therefore, may be a decoy preventing the entry of HSV
into host cells 134,234
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EL-12

IL-12 is produced following an initial encounter with foreign antigen, by cells

such as monocytes, M(j)s, neutrophils, DCs,and antibody-producing B cells 235. The
ability of lL-12 to modulate the immune system was initially related to the induction of
IFN-y synthesis and increases proliferation and cytotoxcity of NK cells and T

lymphocytes 221 . lL-12 is also known to play an important role in inducing differentiation
and expansion of unprimed CD4''T cells to a Thl profile, thus promoting T cell

responses and M(t) activation 139,194,221 Recently, studies have shown a powerful n.-12
enhancement of endogenous immune responses to HIV 25' 22,26^ Leishmania spp. 211,
Plasmodium spp. 1^3^ Mvcobacterium tuberculosis 256- 42

Schistosoma mansoni 240.

In order for IL-12 to play a role in defense against challenge with any particular

agent, host -pathogen interactions would have to result in IL-12 expression. In HSV
infection, at least two reports have shown both in vivo and in vitro production of IL-12

upon viral stimulation 20,100. Whether the elicited IL-12 production plays any role in host
defense mechanisms is, as yet, undetermined. However, studies by Biron et al, on

another herpesvirus, murine cytomegaloviras(MCMV),indicate that IL-12 is highly
effective in controlling infection by inducing NK cells to clear the virus and reduce viral

proliferation

Since both NK cells and Thl lymphocytes are proven to be important in

mediating the defense mechanisms against HSV cutaneous infection, it is likely that viral
induced IL-12 would augment these responses and hence strengthen immune protection.
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Vaccine development aeainst HSV

Vaccine development for HSV started in the 1970s, yet, no licensed vaccines exist
at this time for HSV. Given the considerable success of vaccines against several other

animal herpesviruses, one might wonder why the same is not true for HSV. A major
reason for this is that vaccines against infectious agents work most effectively when used

prophylactically. For the control of human HSV infection, the greatest need is for
vaccines to diminish clinical signs in individuals already exposed to HSV or who carry
the virus in a latent form, since most latently infected individuals suffer periodic

reactivation and disease reexpression. It is this group which clamor for therapeutic
vaccines to minimize or even abolish clinical disease. Although many candidate vaccines
have been touted to fulfill such a role, none have been proven satisfactory upon

independent, double-blind evaluation 207. Recently, enthusiasm for therapeutic vaccines
was rearoused by the results of Straus, et al. 209^ who demonstrated beneficial effects

using an alum adjuvanted glycoprotein vaccine. This particular trial presented the first
controlled data showing that a vaccine could modify the course of a chronic viral
infection in humans. Unfortunately, the study failed to identify specifically the immune

response that correlated with vaccine efficacy. However,the study strongly suggested that
vaccines may be effective therapeutically if they optimally stimulate certain components
of the immune response.

Despite past failures, there are now two HSV vaccines (both using recombinant

glycoproteins) being evaluated for effectiveness both in prevention and treatment of
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primary genital herpes. These studies are being conducted by Chiron-Biocine and
SmithKIine Beecham Biologicals. In addition to the development of subunit vaccines

containing recombinant glycoproteins, other novel HSV vaccine strategies are also being

explored. One approach is the development of genetically engineered, attenuated,

replication-competent HSV vaccines. This strategy, pioneered by Roizmen,involves the
construction of intertypic HSV mutants in which important virulence genes have been

deleted. These mutants produce both type 1 and 2 immunogenic proteins and should, in

theory, protect against infection caused by either HSV-1 or HSV-2

Another

interesting approach is the development of replication-impaired mutant viral strains,
which involves the deletion of a gene required for virus replication. The defective virus

can only be grown on a genetically engineered cell line that expresses the missing viral

gene product. Hence, when animals are inoculated with the vaccine, the virus can infect
cells and produce immunogenic virus proteins but cannot make progeny, thereby

eliminating further spread and replication of the virus

^6. The recent development of

nucleic acid-based vaccines has also provided a novel approach to controlling viral

infections . Intramuscular injection of DNA results in the in vivo expression of the

encoded protein in animals and the subsequent development of both cell-mediated and
humoral immune response to the expressed protein

These myriad approaches are

promising and increase the likelihood that multiple generations of HSV vaccines will be
forthcoming.
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DNA vaccines

Exploration of the use of DNA plasmids encoding antigenic proteins to induce
immune responses by direct injection into animals started in the early 1990s after the
observation that plasmid DNA could directly transfect animal cells in vivo. Termed DNA

or genetic immunization, this approach has been used to elicit protective antibody and
cell-mediated immune responses in a wide variety of animal models of viral, bacterial,

parasitic, and even tumor and autoimmune diseases. The following review summarizes
current knowledge on the vector design, vaccine delivery,immune responses and its
modulation, immunological mechanisms, safety considerations and potential application
of this novel immunization approach.

History

The observation that naked DNA injected into mice could be expressed was

observed as early as 1962 5. However, it was the observation by Wolff and colleagues in
1990 demonstrating prolonged protein expression following intramuscular injection of

naked plasmid DNA that alerted investigators of the potential of DNA immunization 238.
Two reports appeared in 1993 indicating the value of naked DNA,often termed nucleic
acid or genetic vaccines, as potential prophylactic vaccines against infectious

agents ^53,182. Both reports demonstrated that plasmid DNA-encoding proteins from
influenza virus could induce immune responses. Within the last 4 years, DNA vaccines
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have been reported to induce some form of immunity against not only infectious agents,
but also cancer and allergens (Table 1-1). Currently, close to 400 scientific papers related
to DNA vaccines have been published. DNA Vaccine Webpage founded in 1996 by
Whelan at Pasture Institution (http://www.genweb.com/Dnavax/) has become the most
visited website among the bioscience homepages.

Early stages of DNA vaccine development focused mainly on testing the

immunogenecity of the antigen encoded in the plasmid. Most of the research groups

reported successful immune induction with the DNA encoded antigen, including both
humoral and cellular responses. However,immune responses elicited by DNA vaccines

are generally not as effective as those elicited by replicating antigen or protein antigens.
Modulation of the immune responses by DNA immunization has been the major issue in
recent studies. Great effort has been put into enhancing or re-directing protective

immunity by various methods such as co-administration of cytokine DNA,delivering
DNA via vehicles, modifying the promoter, and selectively expressing antigenic epitopes.

Investigations are also underway to resolve fundamental issues related to the mechanisms
of immune induction following DNA immunization. Although pharmaceutical

companies plan to apply DNA vaccines in several clinical trials, the safety issues, such as
the possibility of DNA integration, tolerance induction, and promotion of autoimmune
disease are still major concerns.

Certainly, the arrival of DNA immunization caused a stir in the world of

vaccinology. Although evidence is accumulating that shows DNA can engender
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protective immunity when given prophylactically, whether DNA immunization will be a
superior means of vaccinating against infections which already have effective vaccines,
such as measles and rubella, has been put to question. The future of DNA vaccines may

be in the production of vaccines against agents where traditional approaches have failed
or are unsatisfactory.

Vectors for vaccine use

Basic structures for most plasmids used for vaccination purposes consist of (i) an

origin of replication (ori) suitable for producing high yields of plasmid in bacteria;(ii) an
antibiotic resistance gene for selective growth in bacteria;(iii) a strong eukaryotic

promoter/enhancer, and (iv) an mRNA transcript termination/polyadenylation sequence
for directing expression in mammalian cells. Fig. 1-2. illustrates a typical mammalian

expression plasmid DNA vector, pcDNAS.l (Invitrogen, San Diego, CA).
The methods of preparing plasmid DNA can be divided into three categories. The
first is cesium chloride purification, which provides the purest product, but is time

consuming, and the residue of cesium chloride is toxic to the animal. The second method
is phenolchloroform extraction which is low-cost and simple. The disadvantage of this
method is less purity and low yield. The third method uses a silicon or anion-exchange
column. The use of these commercially available columns is straight forward and can cut

the preparation time to at least 2/3 less than the other two methods.
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Quality control of the plasmid DNA preparation includes elimination of
endotoxin, RNA and ssDNA, and protein contamination, as well as providing for DNA

homogeneity, sterility, identity, and purity. Qiagen,Inc.(San Diego, CA), which is the

largest provider of plasmid DNA purification systems, has listed a summary of quality
criteria for plasmid DNA used for gene therapy (Table 1-2). While biotechnology

companies and several research labs insist that the purity of the plasmid DNA can effect
in vitro and in vivo efficacy of gene expression, research directed by a group of Canadian

scientists compared cesium chloride and anion-exchange-purified plasmid DNA for direct

gene transfer into mouse muscle and showed no differences in efficiency of transfection
with reporter genes or in humoral responses to DNA-based immunization
In vitro expression of the foreign gene encoded by plasmid is always used as an
indicator for the possibility of success in inducing immune responses in vivo.

Surprisingly, the level of gene expression in vitro does not reflect what occurs in vivo.
One study by Xiang, et al, in which the Simian Virus 40(SV40) promoter of the vector

was replaced by the early promoter derived from cytomegalovirus(CMV)without

altering other parameters of the plasmid, showed striking effects on the stability of
expression of rabies virus G protein encoded in the plasmid on transfection in vitro.
Nevertheless, both constructs induced comparable immune responses upon intramuscular
inoculation in mice ^43.

Besides viral promoters, investigators are now using nonviral, tissue specific

promoters in DNA vector design. The rationale is to control the antigen expression and to
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direct a local immune response. Recently,cytokine-driven and muscle-specific

promoters have been used in DNA vaccine and gene therapy

149_

Delivery of DNA vaccine

Intramuscular injection

In 1990, while studying gene therapy for muscular diseases, J. A. Wolff and his

colleagues

injected RNA and DNA expression vectors containing genes for

chloramphenicol acetyltransferase, luciferase, or p-galactosidase into mouse skeletal
muscle in vivo. Protein expression was readily detected in muscle for at least 2 month. To

their surprise, although the efficiency of direct intramuscular gene transfer was not high
enough to treat genetic muscle diseases, this relatively low efficiency of expression (less
than 100 fibers per injection site 38) was able to program cells in vivo to generate antigen
for immunization purposes. Following in their steps, the early studies of DNA vaccines
all used intramuscular injections (i.m.).

Various parameters such as needle type, speed of injection, volume of injection

fluid, tonicity of infection fluid ,type of solute, type of muscle, physiologic condition of
the muscle, and age of the animals were studied in rodent muscle in vivo to evaluate their
effect on the levels of gene expression 239_ xhe results showed that normal saline as an

injection fluid increased the efficiency of expression. Rat and mouse quadriceps muscle

treated with 0.75% bupivacaine before gene injection also enhanced the expression 36.
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Injection to smaller muscle groups such as the anterior tibial muscle, tended to have
better effects than to larger muscle groups 248.
A major concern is about the fate of the plasmid DNA after intramuscular

injection. In vitro experiments were initiated to elucidate the mechanism of DNA nuclear

transport in mammalian cells by microinjection of vector DNA encoding P-gal or
luciferase genes into the cytoplasm of primary rat myotubules in culture. The results
indicated that plasmid DNA entered intact postmitotic nuclei through nuclear pore by a

process common to other large karyophilic macromolecules

236

. The majority of the

injected plasmid DNA was sequestered by cytoplasmic elements. In vivo injection of the
plasmid DNA into muscle also resulted in long term persistence of the plasmid, and gene
expression. Plasmid DNA was demonstrated by quantitative PGR in some of the muscle
DNA samples for at least 19 months after injection 237. xhe methylation pattern of the
plasmid DNA remained in its bacterial form, indicating that the foreign DNA did not
replicate in the muscle cells. Electroporation of total cellular DNA from injected muscles
into bacteria indicated that the plasmid DNA was extrachromosomal 237.

Despite evidence showing that muscle cells are effectively expressing the foreign
gene in vivo, the level of antigen expression seems to be unrelated to the immune

responses elicited by the DNA. First, a strong promoter can change the expression of the

gene, but does not affect the immunogenecity of the plasmid DNA encoding antigen 243.
Second, excision of an injected muscle bundle within 10 minutes of DNA inoculation

does not affect the magnitude or the longevity of Ag-specific Ab responses 218. These
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observations indicate that cells other than muscle are involved in the immune induction

during DNA intramuscular immunization.

Particle bombardment

Particle bombardment is to the injection of DNA coated gold beads directly to the

cytoplasm of a cell by a hand-held bombardment device, called a "gene gun". DNA
immunization with the gene gun requires a much smaller amount of DNA than

intramuscular injection. For intramuscular immunization in mice, 50-100 ug of the

plasmid DNA are common used to induce immune responses. However, with the gene

gun, 200 ng or less of DNA are sufficient for the immunization 5i,212 jhe gene gun has
been used most commonly to inject plasmid DNA into skin, where the LCs,the potential
APCs, are enriched 135,254 xhe gene gun has also been applied to mucosal site to induce
immune responses 1^9,

DNA delivery by a gene gun may exhibit another distinct advantage over other
administration methods. That is, the immune responses elicited by gene gun

immunization tends to establish a Th2 type response. In an investigation by Robinson's

group 60, immune responses generated by different routes and methods of DNA
immunization were compared. It was found that DNA immunization in saline by

intramuscular injection induced a predominantly Thl response with mostly IgG2a

isotype, while gene gun DNA immunization produced a predominantly Th2 response,
with mostly IgGI isotype.
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Intradermal injection

The rationale for intradermal injection (i.d.) of plasmid DNA is that skin-

associated lymphoid tissue, such as DC, may aid the uptake of plasmid DNA and
facilitate immune induction. Compared to intramuscular injection, intradermal

administration requires less DNA,and does not need extra preparation as for gene gun
immunization. As shown in one influenza system, single dose i.d. injections are capable

of eliciting immune responses which last for more than two years

Interestingly,

although both injections occurred within the skin, the Th cell responses induced by
needle injection is Thl type, while a Th2 type profile is induced by gene gun

delivery

179_ These observations however, remain contraversial.

Mucosal delivery

Antigen delivery via mucosal routes is not as efficient as is systemic
administration because of physical barriers at mucosal surfaces. However,immune
induction at mucosal sites seems to be important in providing protection against

pathogens which invade from mucosal surfaces, such as HIV,HSV,and influenza virus.
Several trials on mucosal DNA immunization have been pursued during the past few

years

231-67 _
Immunization of naked DNA orally has resulted in few successes 9"^. Other sites,

such as nasal and vaginal routes seem to be more promising. Both local and systemic

immune responses can be detected following immunization via intranasal and
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intravaginal pathways. Moreover, the efficiency can be enhanced with adjuvants which
facilitate entry of the large negatively charged DNA molecules into tissues. Such adjvants

include cholera toxin B '20^ liposomes 108^ dry powder (notes from IBC's 3rd Annual
Genetic Vaccines and Immunotherapeutic Strategies Meeting by Joanne Curley), and
cochleates

Other delivery routes

Co-administration of plasmid DNA encoding a reporter gene with cationic lipids

intravenously (i.v.) not only leads to marker gene expression but also induces detectable
antibodies and CTL responses. The immune responses induced by this administration

method are comparable to those seen following i.m. injection of DNA in saline.

Intraperitoneal injection (i.p.) of the same complex, or a combination of DNA with pH
sensitive liposomes either i.v. or i.p. fails to induce immunity, although the marker gene

expression can be detected. These observations by Yokoyama, et al. 250 suggested that
when evaluating various promoter constructs, gene expression may not adequately replace
the direct measurement of biological outcomes.

Immunity induced by DNA vaccine

Non-specific immune responses

Among foreign macromolecules, bacterial DNA attracted little interest from

immunologists and was regarded as generally irrelevant in the encounter between bacteria
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and host. In recent years, however, because of a series of provocative studies, the concept
of DNA as an antigen has been remarkably transformed. These studies demonstrated that
DNA fulfills the capabilities of antigenicity predicted by its structure, and has powerful
OO /I

^

y

actions on the immune system ' . These actions include not only B cell activation^

but stimulation of cytokine produciton 8M10 and induction of specific antibodies "^2.
These properties reflect structural microheterogeneity and result from immunostimulatory

sequences(ISS) which center on unmethylated CpG(AACGTT)residues which are
much more common in bacterial DNA than in mammalian DNA

The host uses these

differences between bacterial and mammalian DNA as an effective screen for the

presense of infection, irrespective of the nature of the organism. Therefore, bacterial
DNA may function as a major stimulus for innate immunity
IL-12 and TNF-a are the major cytokines produced from Mcjis upon CpG

sequence stimulation in vitro

These cytokines are responsible for activating NK and T

cells to produce XFN-y, which is an important mediator of innate defense mechanisms.
Plasmid DNA used for immunization often contains CpG sequences in the ampicilin

resistant gene. To examine whether the CpG motifs present in these plasmids contributed
to the immunogenicity of DNA vaccines, in vitro experiments showed that plasmid DNA

with CpG induced production of the same cytokines stimulated by bacterial DNA.In vivo
experiments showed that the immunogenicity of a DNA vaccine was significantly
reduced by methylating its CpG motifs, and was significantly increased by

coadministering exogenous CpG-containing DNA
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CpG sequences are also involved

in the activation of B cells and stimulating IL-6 production in vitro, which may augment
IL-12 secretion by B cells

The molecular mechanisms involved in the immuno-stimulatory effects of CpG

motifs have yet to be clarified. DNA may enter cells by bulk phase endocytosis or

pinocytosis 228^ or by binding to cell surface receptors

Once inside cells, bacterial

DNA could induce cellular effects by a number of mechanisms, including binding

transcriptional regulators,forming triple-stranded DNA to alter transcriptional activity, or
binding to mRNA to block translation of key regulatory protein by an antisense
mechanism.

The effects of CpG sequences seem to not only induce significant innate

immunity, but also to promote the humoral and cellular immune responses against
environmental and plasmid-encoded antigens. Reports from Sato and Raz, et al.

have

shown that the elimination of CpG motifs from the plasmid backbone of a P-

galactosidase-encoding DNA plasmid significantly reduced its immunogenicity and that
the ISSs enhance Thl responses to DNA vaccines. These findings support the model

postulated by Fearon and Locksely 58, which states that innate immune responses create
an immune milieu conducive to the development of antigen-specific immunity.

Antigen specific antibody responses

Immunization with plasmid DNA has proven to be an effective way of eliciting
humoral immune responses specific for a diverse array of proteins. Antibody responses
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induced by DNA vaccination were first demonstrated in mice against human growth
hormone and human-a antitrypsin following gene gun injection of DNA encoding these

proteins 212. Protein could be detected in the serum for months to years, thereby
providing continued antigen stimulus. Antibodies against viral proteins were first
demonstrated after i. m. injection of DNA encoding influenza nucleoprotein(NP)and

hemagglutinin(HA)224, Other reports subsequently confirmed the ability of injected
DNA to generate humoral immune responses against infectious pathogens.(See a list in
Table 1-1)

In some cases, these antibodies have contributed to protection against challenge

with the relevant infectious pathogen (See Table 1-1), indicating that the antigens

expressed in vivo after DNA vaccination can assume a native structure with intact

epitopes, including conformational epitopes, and induce neutralizing antibodies. Such
antibodies have been demonstrated in sera of animals injected with DNA encoding HIV

envelope protein 232^ herpes simplex virus glycoproteins

and influenza HA 224,

The duration of antibody responses induced by DNA vaccination is long-lived in

mice, as demonstrated with influenza NP 128^ hA 99 ,hepatitis B surface antigen 38 and

hepatitis C core protein '21. In some nonhuman primates, antibodies appear to be more
short-lived ^35. However, this may reflect differences in the longevity of humoral immune

responses in these species in general, since this is also true for protein subunit, wholeinactivated and recombinant virus vaccines 135,
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The antibody isotypes induced are generally IgG, but serum IgM and IgA have
also been detected

Low levels of HA-specific antibody-forming cells have been

observed in the spleen and bone marrow following gene gun immunization in mice with
HA DNA 59. So far, few or no mucosal IgA antibodies have been detected after i. m.
injection or particle bombardment with DNA vaccines.

Antigen-specific cytotoxic T cell responses

MHC class I-restricted CD8"^ cytotoxic T lymphocytes were detected when lymph

node or spleen cells from mice immunized i.m. with plasmid DNA encoding viral
antigens were restimulated with the antigen. Effector CTL that recognized epitope

peptides appropriate to the H-2 restriction element have been demonstrated in mice
immunized with DNA encoding the NP from influenza A virus 224^ hBV surface

antigen

and core antigen 119^ and HIV Env 197^ and also in non-human primates

immunized with DNA encoding HIV Env '28

some cases, CTLs induced by DNA

vaccines were capable of recognizing and killing influenza 224^ vaccinia- HIVgpl60 '28^
adenoviurs-rabies glycoprotein 242^ LCMV 249^ and HSV-1

infected targets. A

current study on plasmid DNA encoding an epitopic minigene from HSV demonstrated
that CTLs induced by the minigene construct lyse epitope-specific targets better than
virus infected targets. This may indicate that the effector CTL induced by DNA
immunization may have a lower affinity to viral infected targets compared to CTLs
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generated during natural infection 253. Anti-NP CTLs were found to persist for more than
2 years after immunization with influenza NP DNA ^8.
Gene gun immunization also induced antigen-specific CTL responses. However,
the CTL response may be suppressed by the Th2 responses induced by gene gun
immunization. Fuller et al. reported in 1994 that mice immunized intra-epidermally with

the gene gun three times with 4 ug each of plasmid DNA encoding gpl20 and lug of Rev
DNA,CTL responses were detected after two immunizations but were diminished after
the third immunization, while antibody response appeared only after a third dose. The

suppression of CTL responses could be recovered by administration of antibody to
IL-4

A combined approach of i.m. injection followed by i.d. gene gun inoculation

was used to generate CTL recognizing a V3 loop peptide of HIV as well as virusneutralizing antibodies and antibodies to HIV p24 in mice. CTL responses of splenocytes
restimulated in vitro with the V3 loop peptide persisted to 15 weeks after the final
immunization 135.

The frequency of CTL precursors after DNA immunization has not been wellcharacterized. In one study with gene gun immunization using DNA encoding the NP of
LCMV,NP-specific CTL precursors were found in the spleen of immunized mice at

frequencies of approximately 10"^ after one immunization, and 6 x 10'^ after 4
immunizations 254. in lymph nodes the CTLs appeared as early as 4 days after
immunization 254.
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Helper T cell responses

The type of T cell help elicited during infection can have a critical effect on the
outcome. A typical example is infection with Leishmania spp., which is lethal in mouse
stains that develop Th2 responses to the infection, whereas strains that develop Thl

responses become immune

The type of T helper cells to particular vaccines may be a

critical determinant for efficacy of the vaccines. Intramuscular immunization with DNA

plasmids encoding a variety of antigens, such as influenza HA and NP 224^ and HIV Env,
Gag

232^ M. tuberculosis antigen 85

and HSV gB ^^3 generate T lymphocyte

responses manifested by proliferation of antigen-specific T cells, and secretion of

cytokines during in vitro culture of splenocytes from immunized animals. Proliferation of
lymphocytes from immune animals ranged from 3 to 100 times greater than cells cultured
without antigen, significantly higher than control animals. Supernatant from these
cultures contained high levels of IL-2 and IFN-y, with little or no IL-4 or IL-5, indicating
that these DNA vaccines elicited Thl like cytokine responses. In some reports, these

responses were maintained in vaccinated animals for at least a year, indicating that longlived memory responses were generated

Vaccination using a gene gun, which delivers DNA-coated gold particles to the

epidermis, appears to bias immune responses toward Th2-like response

Currently,

there is no conclusive explanation for these differences.

The antigen encoded in the plasmid DNA may also influence the type of T help
cells induced by the vaccine. For example, i.m. injection of plasmid DNA encoding a
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variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and
activates Th2 immunity 230_

Immune mechanisms of DNA vaccine

Immunization by direct transfection with DNA has raised a number of questions

regarding the mechanisms of induction of immune responses. Such questions include
where the DNA is expressed, how the DNA is up taken by somatic cells, how antigens

are processed and presented to the immune system. Little was known about the exact
mechanisms involved in the immune induction by DNA; however, progress has been

made during the past few years. With the development of more sophisticated techniques,
some of these questions will be answered soon.

DNA uptaking and expression

When injected into the muscle or other tissues, the majority of the DNA remains
in the extracellular space. The mechanisms of DNA uptake by tissue cells, especially non-

phagocytic cells, are not yet known, but several studies have investigated this event as it
occurs in myocytes. A survey of nonnuclear membrane-associated DNA binding proteins
from skeletal muscle conducted by Hgstrom, et al. ^9, revealed several sarcoplasmic

reticulum-restricted DNA binding species, indicating their possible role in the transport of

plasmid DNA into the sarcoplasma. In vitro experiments of microinjecting plasmid DNA
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into primary muscle cells or cell lines have shown that the DNA can enter the nuclei
though the nuclear pore ^0.
DNA immunization produced foreign antigen in myocytes following i.m.

injection, or in cutaneous epithelium following delivery of DNA by gene gun. Early
experiments by Wolff et al. 236, showed that among several tissue cell types, myocytes are
the most efficient at expressing foreign antigens encoded in the plasmid. Protein

expression in other tissues after i.m. injection rarely occurs '66. jhe proportion of tissue
cells expressing the antigen is relatively small. According to Davis, et al, and Acsadi, et
al, less than 100 fibers or 1% per injection site are expressing the antigens f 38.
Although early studies by Wolff, et al

using P-galacosidase-encoding DNA found the

protein expression in muscle for a prolonged time, the measurement of this particular
protein may not reflect the continuous expression of the protein. A later report from
Davis's laboratory showed that HBsAg-expressing muscle fibers are destroyed around 10

days after injection of DNA in mice, by immunohistochemistry and electron microscopy.
In SCID mice, the myofiber destruction does not occur, indicating that the destruction is
imunologically mediated 39.

Antigen processing and presentation during DNA immunization
One of the interesting aspects of DNA immunization is the nature of antigen

presenting cells(APCs)responsible for the induction of CTL responses. The ability of
secreted proteins to be endocytosed and to enter the pathway of antigen processing that
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leads ultimately to presentation via MHC class 11 molecules is v^ell known. The

mechanisms by which foreign antigens might be presented via MHC class I molecules to
naive CD8"^ T lymphocytes may be more complex. The opportunity of plasmid DNA to
be directly transfected into a professional APC are considerably small. Therefore, the
induction of an immune response to the encoded antigen may employ cooperation
between somatic cells and APCs to varying extents.
Extensive studies of the mechanisms of CTL induction during DNA vaccination

have been done using i.m. models. Current proposed means by which MHC class Irestricted CTL might be induced after DNA vaccination include (Fig. 1-3): (i) antigen

presentation mediated directly by transfected myocytes;(ii) professional APCs becoming
transfected and serving as the APCs, and (iii) transfer of antigen from transfected
myocytes to professional APCs.

It has been shown that professional APCs present antigen in an MHC class Irestricted manner after DNA immunization, and that muscle cells can produce the antigen

that enters this pathways. Evidence suggests that production of antigen by muscle cells
alone is sufficient to induce CTL responses. This was illustrated by studies in which

C2C12 myoblasts were stably transfected with influenza NP DNA and then transplanted

into histocompatible C3H mice. An H-2K'' restricted CTL response was induced even
though synthesis of the antigen was limited to the myocytes 223_ Therefore, transfection of
professional APCs is not required for induction of CTL. In vitro evidence that myocytes

can express MHC-I and II molecules in the presence of IFN-y^- 233, which could be
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induced non-specifically by bacterial DNA, also supports the possibility of antigen
presentation by muscle cells.

To prove the hypothesis that the principal APC responsible for induction of CTL
following i.m. injection of plasmid DNA are derived from the bone marrow, parental
F1 bone marrow chimeras were immunized with plasmid DNA encoding influenza NP by

i.m. injection, or injected with myoblasts stably transfected with a gene encoding NP.
Detectable CTL responses were seen only to the peptide presented by the MHC class I
molecules found on the donor bone marrow cells

These data are supported by studies

with SCID mice, who lack functional T and B cells, but have normal APCs. Injection of

plasmid DNA in H-2'' or H-2'' SCID mice that had been reconstituted with normal
spleen cells induced CTL restricted by the haplotype of the SCID recipient. If F1 bone
marrow and spleen were transferred, CTL restricted by either haplotype were obtained,

suggesting that MHC class I-restricted antigen presentation in the model can be facilitated
by bone marrow-derived APCs

Others also have similar observations in mice

immunized with directly transfected APCs 28,140,

The mechanism by which transfer of antigen between somatic cells and

professional APCs is not known. One hypothesis is that antigens (or their epitopes)

synthesized in somatic cells of the host can be transferred to an APC for presentation in
the context of MHC class I

Experimental evidence at least from two separate systems

supports this hypothesis. First, CT26,a colon adenocarcinoma cell line of the H-2''
haplotype, transfected with influenza NP DNA was used to inununize B6 > CB6 F1
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mouse bone marrow chimeras. An H-2D''- restricted CTL response was induced, although

CT26 cells did not express H-2D''91. Second, when C2C12 myoblasts (H-2K'') were
transplanted into (BALB/c x C3H)F mice,CTL responses were obtained that recognized

distinct peptide epitopes presented by both H-2K''and by H-2K'', even though the
myoblasts did not express H-2K''. These responses were observed even when the
myoblasts were transplanted, where they would not be expected to fuse with host
cells 223.

The formation of epitope peptide complexes with MHC class I molecules in DNA

immunization requires TAP (transporter-associated antigen presentation) in the bone

marrow-derived AFC,because bone marrow chimeras made by grafting TAP"'" bone
marrow into TAP"^'"*" recipients were unable to respond to antigen expressed in transfected
cell lines 90.

In contrast to vaccination by i.m. injection of DNA,vaccination by particle
bombardment results in the transfection of cells of the dermis and epidermis by direct

deposition of DNA-coated gold beads. Therefore, professional APCs,such as LCs,
resident in the skin are directly transfected and can serve as APCs. Biopsy of the skin

target site up to 24 hours after gene gun bombardment showed completely abrogated
antigen-specific immune response in the majority of mice,indicating that transfected cells
in gene gun-bombarded skin play a central role in DNA-initiated antibody and CTL
responses 218.
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Safety considerations for DNA vaccine

Potential for integration

Integration of plasmid DNA into the genome of host cells could be mutagenic,
carcinogenic and/or oncogenic. Integration may occur either randomly, or as a result of
homologous recombination. Studies have defined the optimal conditions for achieving

integration as the result of homologous recombination as (i) concurrent replication of the
host and plasmid DNA,and (ii) the presence of large (>600bp)closely spaced regions of
homology between the host and the plasmid. In most cases of DNA immunization, the
plasmid does not contain an origin of replication that is functional in eukaryotic cells. The
transfected cells, including myocytes and M(j)/DCs are nondividing cells, and the plasmids
contain very limited sequence homology with mammalian DNA.In addition, although
random integration may occur more frequently than homologous recombination, direct

studies of integration in mice injected with plasmid DNA with sensitive PGR methods
have yet to detect integration of the injected plasmid

.

Potential for induction of immunologic tolerance

The amount of antigen produced after DNA immunization is thought to be small,

and the expression of antigen after DNA immunization may persist for weeks or months.

Thus the possibility that DNA immunization might induce unresponsiveness can not be
excluded. However, to date, tolerance induced by intramuscular injection of DNA has not

been reported, even with subimmunogenic doses of DNA in vaccine form
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In contrast,

Mancini, et al.

have shown that DNA iimnunization abolished the state of tolerance to

HBsAg that normally existed in transgenic mice expressing HBsAg under the control of
an endogenous viral promoter. In Rhesus monkeys immunized by gene gun particle
bombardment, repeated immunization with a mixture of constructs encoding SIV Gag
and Env led to a sharp decline in antibodies to Env, although antibody and cellular
responses to Gag remained high 1^5.
In some systems, immunizaiton of 2-5 day old mice with DNA vaccines was
observed to induce neonatal tolerance rather than immunity ^55. However, this finding

was contradicted by others who have shown that neonatol animals can develop efffective
humoral and T cell responses after immunization with DNA '44- ''^6.

Potential for induction of autoimmunity

Theoretically, the induction of autoimmunity by DNA immunization is possible
and might occur as a result of immune-mediated destruction of cells during DNA
immunization. Intramuscular injection of DNA in saline solution can induce a severe, but

localized inflammatory response 248. However,such inflammatory reactions also occur in
the course of viral and bacterial infections, as well as in normal processes of tissue

remodeling. It appears unlikely that DNA vaccines would pose any greater risk in this
regard than conventional viral or bacterial vaccines.
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Potential for induction of anti-DNA antibodies

Another safety consideration involves the potential induction of immune

responses against the plasmid DNA itself, which may be involved in certain autoimmune
disease such as systemic lupus erythematosus. Generally, dsDNA does not readily induce
anti-DNA antibodies unless it is denatured, or coupled with methylated bovine serum

albumin, or coadministrated with complete Freund's adjuvant "^2. Although circulating

nonpathogenic anti-bacterial DNA antibodies can be found in normal humans and
animals, the specificity of reactivity is non-cross-reactive with mammalian DNA

In

addition, vaccination of normal animals with purified DNA resulted in the induction of
little or no anti-DNA antibodies as measured by ELISA,immunoblot, or

radioimmunoassay 94,105_ Therefore, while it is not yet known whether DNA vaccines
will induce anti-DNA antibodies in humans, preclinical animal studies suggest that this is
unlikely.

Potential applications of DNA vaccine

Modulation of Immunity

Although in preclinical studies the administration of DNA vaccines was shown to
be an effective means of inducing antibodies and CTLs,the efficacy of DNA vaccines

compared to replicating vaccines is still relatively weak. In order to enhance the immune

responses induced by DNA immunization, use of formulations to optimize DNA stability
or distribution in the muscle, and co-expression of immune molecules to affect the
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processing and presentation of antigen have been attempted. Bupivacaine, a local
anesthetic, has been studied in facilitating the uptake of DNA into muscle cells
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. It

causes local dilation of vessels at the site of injection, activation of M<|)s and other APCs,

and increases the DNA uptake function of myocytes. Weiner demonstrated the

advantages of using bupivacaine to enhance DNA immunization with HIV constructs 232.
Other adjuvant-type compounds such as vitamin D3(VD3), which is capable of activating
and enhancing the phagocytic properties of macrophages, may also influence immune
responsiveness. Using VD3 along with DNA expressing glycoprotein D of HSV-2,
Kriesel and colleagues showed an enhanced immune response against HSV challenge

following i.m. vaccination'

in recent studies, DNA vectors expressing cytokines have

been shown to be biologically active in situ and to affect immune response against

coexpressed antigens. Granulocyte macrophage-colony stimulating factor(GM-CSF)has
been shown to have a stimulatory effect on both humoral and cellular immune responses

to rabies virus glycoprotein 241 and HSV gB antigen (see Part IV). B7 co-stimulatory
molecules have also been co-expressed to enhance the immunity against tumor and other

pathogenic antigens 29- 93.
Co-administration of cytokine DNA can also be used to tailor the immunity

induced by the DNA encoded antigen. Co-expression of IL-12 has been shown to

enhance CTL responses, shift Th responses to Thl type, and inhibit antibody production
in DNA vaccines against HIV 102 in contrast, coimmunization with an IL-4-producing
construct induced differentiation of Th cells toward a ThO subtype, and suppressed HCV
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core-specific CTL activity ^9. Taken together, these studies indicate DNA-based
immunization may be modified by local cytokine production at the site of antigen
presentation.

The ISS in plasmid DNA also serves as a modulator of the immune responses.

Raz, et al.

recently demonstrated that delivering p-galactosidase antigen by DNA

induces Thl responses, while the protein form of the antigen causes a major Th2

response. They suggest that the ISSs encoded in the plasmid help to promote the switch
from Th2 to Thl. Another interesting observation is from the study using plasmid DNA

encoding a Leishmania antigen, LACK,which itself strongly induces IL-4 production and
reduces resistance to Leishmania major infection in BALB/c mice. However,LACK

DNA induces predominantly IFN-y production, and conferred protection against parasite
challenge in BALB/c mice .

Neonatal vaccine

The lack of protein components in DNA vaccines represents an advantage because
responses are less likely to be affected by a preexisting immune response. This might be a

particular advantage in terms of successfully immunizing infants who maintain matemal
antibodies. Despite reports that DNA immunization failed to induce immune responses
in newborn mice '55^ at least two recent studies have shown that DNA vaccines can

successfully induce both humoral and cellular immune response in neonates. As study by
Manickan, et al. ^44, evaluated the response of neonatal mice to immunization with naked
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DNA encoding an HSV protein, and determined if maternally derived HSV antibody
interfered with immunogenicity. Their results showed that neonatal mice developed
effective humoral and T cell responses after immunization with DNA vaccines. A second

investigation is from Prince, et al.

To determine whether DNA-based immunization

could protect newborn chimpanzees against a challenge infection with hepatitis B virus,
two chimpanzees were immunized on the day of birth with a plasmid encoding a hepatitis
B surface antigen, and boosted at 6 and 24 weeks. Both animals produced transient

antibody to the hepatitis B surface antigen. Following challenge with hepatitis B virus at
33 weeks the two immunized animals developed anamnestic antibody responses, but

neither to hepatitis B surface antigen or core protein, the conventional markers of

hepatitis B infection. Thus, these experimental results indicate that DNA vaccines might
provide a useful means of immunizing young animals that still possess high levels of
potentially interfering maternal antibody.

DNA vaccines in the control of immuoinflammatory diseases

An immune response to an infectious agent can sometimes cause tissue pathology.

In such immunopathologies, the logical approach is to tailor the immune response and/or
induce a response that is protective rather than tissue-damaging. Manipulating the

immune responses with DNA vaccines that selectively engender protective inununity is a
theoretically feasible strategy, particularly if DNA vaccines can be designed that are
composed of minigenes which encode appropriate epitopes along with adjuvant
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molecules that will push the immune response in one or another direction. Some of the

important infectious diseases with immunopathological lesions in man include hepatitis
B,respiratory syncytial virus pneumonitis, dengue, and perhaps, certain manifestations of
HIV 141. dNA vaccines may lead to new strategies for the control of these infections.

In some diseases, prevention is probably as important as treatment, such as in

herpes virus infections. Investigators have begun to ask if DNA vaccines can change the
course of disease when used prophylatically. Some evidence in the LCMV system
indicates that immunization with DNA encoding either the nucleoprotein or glycoprotein

genes diminishes the severity of lesions resulting from subsequent cerebral infection with
virus 254. DNA vaccines have also been shown to curtail hepatitis in HBV-transgenic

mice 138. Evidence is currently available indicating that the use of DNA may influence

inflammatory diseases. A recent report on LPS-induced endotoxic shock illustrated that
DNA encoding IL-10 and TNF receptor p55 is able to reduce LPS-induced endotoxic
shock and increase the number of survivorsi®3. In the herpetic stromal keratitis mouse

model, Daheshia, et al. 33 demonstrated that topical administration of plasmid DNA

encoding IL-10 suppressed ongoing ocular inflammatory disease. These studies indicate

the feasibility of manipulating inflanunatory responses locally as well as systematically
with DNA encoding appropriate cytokines.
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DNA vaccine in expression library immunization

The identification of the protective antigens of a pathogen is difficult and in most

cases time consuming. This is particularly true for protection that requires cellular

immunity, since certain types of vaccines do not generally induce CTLs. Furthermore,
testing specific antigens requires that they be available in a purified form. With DNA
vaccines, CTLs are readily induced, and one needs only to have the cDNA encoding the

antigen. The process of vaccine antigen discovery may be simplified by a recent and
exciting application of DNA vaccine technology. Barry et al. developed a method,
termed "expression library immunization" to test mixtures of DNA plasmids containing
fragments of a pathogen's genome for protective efficacy. Vaccination with mixtures
containing 3000 distinct plasmids from a Mvcoplasma pulmonis cDNA or genomic DNA
library was shown to confer protection in a mouse challenge model, indicating that at
least one of the plasmids encoded a protective antigen. By successive fractionation and

testing of these mixtures it may be possible to identify the protective fragment encoded in
the plasmid, although to date such fractionation and identification has not been reported.
Indeed, the use of cDNA expression libraries may prove superior since fragments of

genomic DNA may not encode a relevant protein. Such approaches may greatly facilitate
the identification of vaccine antigens.
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Table 1-1 Experimental models used for DNA vaccines

PATHOGEN / ANTIGENS

Borrelia burgdorferi / OspA

Bovine Herpesvirus / Glycoprotein

I.R.

ANIMAL

Ab, and CTL

Mice

Cattle; Mice

Ab

PROTECTION

yes
no

REF.

136
32
170

Human Cytomegalovirus / ppUL83

Mice

Ab

Marine Cytomegalovirus / pp89

Mice

CTL

Hepatitis B Virus /HBcAg

Mice

Ab, and CTL

119

/HBsAg

Mice

CTL

13

Chimpanzee

Ab

37

Rabbit; Rat

Ab

Mice

Ab, and CTL

Hepatitis C Virus / core/ E2

yes

73

38
-

215
-

Mice

Ab, and CTL

yes

143

/ ICP27-1

Mice

CTL

yes

145

/gD-1

Mice

Ab

yes

71

/gD-2

Guinea pigs

Ab

yes

14

Non-human

Ab, and CTL

Herpes Simplex Virus / gB-1

Human Immunodeficiency

Virus-1/ envelope protein

yes

15

primates
232

Mice

Ab

Influenza Virus / HA

Mice

Ab

yes

182

/NP

Mice

CTL

yes

224

Ferrets

Ab, and CTL

yes

Mice

Thl

yes

Leishmania major / gp63
/LACK

Lymphocytic Choriomeningitis

Mice

Thl and CD8''

Mice

CTL

Virus / Glycoprotein
/ Nucleoprotein

74

-

yes
.

45
244

76
148

Table 1-1 (continued)

PATHOGEN / ANTIGENS

ANIMAL

I.R.

Measles Virus / Nucleocapsid

Mice

Ab, and CTL

Mice

Ab, and CTL

PROTECTION

REF.

20

/ Hemagglutinin
Mvcobacterium tuberculosis

93
213

/ hsp65; Antigen 85
Mvcoplasma pulmonis /

122

Mice

Ab, and CTL

Papillomavirus / LI

Rabbit

Ab

yes

46

Plasmodium voelii

Mice

Ab, and T cell

yes

88

Mice (PrPO/0)

Ab

DNA expression library

/ Circumsporozoite protein
Prion Proteins / PRNP

115

Rabies Virus / Glycoprotein

Mice

Ab,and CTL

yes

242

Rotavirus / VP4, VP6, VP7

Mice

Ab,and CTL

yes

85

Schistosoma iaponicum / Sj97

Mice

245

Ab

Monkeys

Ab,and CTL

no

135

Tetanus Toxin / Fragmen C

Mice

Ab

yes

2

Toxoplasma gondii / p30 Protein

Mice

Ab

tumor/mutant p53

Mice

CTL

yes

24

Autoimmune Encephalomyelitis

Mice

Th2

yes

230

Mice

Thl

yes

179

Simian Immunodeficiency
Virus / Env; Gag

3

/T-cell receptor

Model allergy / P-gal

- not mentined in the Ref.
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Table 1-2 Quality criteria for plasmid DNA bv Oiagen for gene therapy research

Quality

Criteria
Endotoxin

DNA homogeneity

LAL" test < 100 E. U./ mg
> 90% ccc''

RNA + ssDNA

agarose gel/HPLC

E.coli genomic DNA
Protein

< 50 ug/mg (Southern blot)
<10 ug/mg of plasmid DNA

Sterility

no colonies after 21-day tryptose

Identity
Purity

restriction digestion

broth culture

spectrophotometric scans
between A220 2nd A320

A260/280

1.75-1.85

Potency

transfection experiments

^ LAL,limulus amebocyte lysate;" ccc, covalently closed circle;' HPLC,highperformance liquid chromatography.

Source - Qiagen Technical Service
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Inoculation site

( mucosal or skin)

Dorsal root ganglia

Retrograde transport of viral particles
along peripheral sensory nerves

Replication in the epithelium
producing vesicles

to

Anterograde transport of infectious
viurs to epithelia surfaces along

Dorsal root ganglia

sensory nerves

o-

(9 ^

Fig. 1-1 Scheme of cutaneous HSV infection

>—
wo o w

CO:>< « tti uu ujCD oj^X

pcDNA3.1 (+/-)
5.4 kb

Fig. 1-2 pcDNAS.l (Invitrogen)
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Plasmid DNA
Intramuscular DNA

Direct transfect into

Non-specific infiammatory

Tissue

cells infiltration

(myocytes,epithelium cells)

i^reting expressed
..gntigen

Enhance

Antigen Presentation
by APCs(B cells, Mcj) and DC)

Antigen Presentation
by myocytes or epithelium cells
VO

MHC-I-Ag

CDS"^

fM(j)& DCj

B

Help

MHC-II-Ag

CD4^

Fig. 1-3 Mechanisms of DNA immunization

(M(t)& DCJ
MHC-I-Ag

CDS"^

Part II

Role of Interferon Gamma in Immunity to Herpes Simplex Virus
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Rationale and Objectives

IFN-y regulates multiple aspects of the immune system, including activation of
macrophages, up-regulation of MHC class I and II expression, induction of antibody
class switching to IgG2a, suppression of IL-4-induced class switch to IgE and IgGl, and
mediation of various aspects of the delayed-type hypersensitivity and cytotoxic reactions.

The role of IFN-y in host defenses against viral infection, therefore becomes complicated.
Previous studies in murine models have revealed that protection against acute cutaneous

HSV infection is controlled by IFN-y,independent of CD4^ and CDS"^ T cells. This

protection is reversed in mice depleted of IFN-y by neutralizing antibody 24. However,
questions still remain to be answered, such as whether mice can develop immunity to
HSV in the absence of IFN-y, what type of immunity is generated in the absence of IFN-

y, and whether compensatory mechanisms exists for IFN-y depletion in host defenses
against HSV. In order to investigate these issues, a transgenic mouse model which does
not express a functional IFN-y gene(gamma interferon knock-out, GKO)has been chosen
for this study. The difference between the transgenic model and the antibody depletion
model is that compensation of the loss of the cytokine should be well-developed in the
gene knock-out mouse.

Thus, in this study, the objective was to test the hypothesis that IFN-y is an

important mediator for both innate and adaptive immune responses, playing an essential
role in viral clearance during cutaneous herpes simplex virus infection. Specific aims
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were;

(1) to compare the susceptibility of mice in the presence(BALB/c)and absence(GKO)
of fFN-y to HSV skin infection;

(2) to characterize the specific immunity to HSV in GKO mice and ,

(3) to investigate the role of IFN-y in T cell mediated protection against HSV zosteriform
challenge by adoptive transferring immune T cells from GKO mice to IFN-y-depleted
athymus mice, and subsequently exposing the recipient mice to virulent HSV infection.

Introduction

Herpes simplex virus(HSV)infects cutaneous and mucosal surfaces and the
resultant lesions initially represent viral induced damage, and subsequently are the result

of inflammatory reactions orchestrated by immune T cells

22. The inflammatory

events usually result in viral clearance, although not before the virus gains entrance into
the nervous system where latency occurs 20. Cellular components of innate immunity
contribute to the immunity, but the infection is not contained unless T cell function is

intact 3. Both major subsets of T cells participate in recovery from HSV,but at least at

cutaneous sites, 004"^ T cells predominate in humans, and in the BALB/c model 22.
Actual mechanisms by which viral clearance is achieved by innate or immune cells is
unresolved, but considerable evidence suggests that interferons, especially EFN-y, are

intricately involved. Indeed, recent reports indicate that IFN-y is an essential participant
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for both €04"^ and CDS'" T cell-mediated clearance of HSV from cutaneous sites 24.

Another study showed the necessity for IFN-y to control acute infection of the nervous
system

In this study we revisited the issue of essential participation of IFN-Y
control of cutaneous infection with HSV using mice genetically unable to produce IFN-y

because of the genetic knock-out. The results showed an apparent requirement for IFN-y
to contain the initial infection, but the functions mediated by T cells appear to proceed

effectively in the absence of IFN-y. Accordingly we interpreted the results to indicate that
IFN-y may be a critical mediator of natural immunity to HSV,but its role may not be
essential during the specific phase of immune defense.

Materials and Methods

Mice

GKO mice, originally generated on the 129/Sv (H-2'') background, were bred to

BALB/c mice (H-2'') and back-crossed four times to generate H-2'''^ GKO mice. Pairs of
such mice were kindly supplied to us by Dr. Tim Stewart, and were then maintained by
brother-sister mating. Subsequent GKO and wildtype litters were screened for IFN-y

gene by tail DNA PGR using the primers provided by Genetech (South San Francisco,
CA). 3-4 weeks old female GKO and wildtype(wt) mice were used in the studies. For

adoptive transfer experiments,4-5 weeks old female nu/nu (H-2^) mice obtained from
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laconic Farms, Inc.(Germantown, NY)were used. All mice were housed in the

facilities which are accredited by the American Association for Accreditation of
Laboratory Animal Care.

Virus and Viral challenge

HSV-1 strain KOS and strain 17 were used and prepared as described previously

21. Mice were infected intracutaneously using the mouse zosteriform model 23 exactly as

described previously 12. Briefly, before challenge, the left flank of the mice was depilated

by using a hair clipper (Oster animal Hair Clipper, Milwaukee, WI), and a chemical

depilator, Nair (Carter-Wallace, NY). After depilation, the mice were anesthetized using
metofane (Pitman-Moore, Mundelein, EL) and a total of 20 scarifications were made in an

approximately 4-mm ^ area. To such scarifications, 10 ul containing various amount of
HSV-1 strain 17 were added and gently massaged. Animals were inspected daily for the

development of ipsilateral zosteriform lesions, general behavioral changes, encephalitis,
and mortality. The severity of lesions were scored as follows:0= no lesions; 1= vesicle
formation; 2 = erosion and ulceration of the local lesion; 3 = mild to moderate ulceration,
and 4 = severe ulceration, hind limb paralysis, and encephalitis. Animals were
euthanarized if in distress.

Immunization of mice

Mice were immunized on day 0 with 2 x 10^ FPU UV-inactivated HSV-l.KOS,
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and on day 7 with 2 x 10® PFU live HSV-l.KOS in 100 ul of HBSS (Hanks balanced salt
solution) intradermally in each hind footpad and at the earbase. Similarly, 100 ul of
HBSS were given to the mice as a control.

Antibody assays

Sera were collected from immunized mice and checked for HSV-specific total

IgG,IgG2a and IgGl by standard ELISA as described elsewhere

Briefly, the ELISA

plates were coated with 100 ul of HSV-1-infected cell lysate (ABI, Columbia, MD)or
anti-mouse IgG as standard, in carbonate buffer(pH 9.8). Serum samples were diluted
1:200 in PBS and run in duplicated wells, with either purified mouse IgG,IgG2a or IgGl
as standards, followed by incubation with horseradish peroxidase-conjugated goat anti-

mouse IgG,IgG2a, or IgG at 37° C for 2 hours. All antibodies were purchased from
Southem Biotechology Associates, Inc.(Birmingham, AL). 2, 2-azino-bis-3-ethylbenzthiazoline-6-sulfonic acid (ABTS,Sigma Chemical, St. Louis, MO)substrate was used
for color development. Antibody concentrations were determined from the standard
curve. Mice serum responses were measured individually. The standard deviation of

serum antibody concentrations are based on individual serum samples of 4-5 mice per
group.

Cytoklne Assays

Single cell suspensions of draining lymph nodes pooled from immunized mice
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were cultured in vitro with m.o.i. = 1.5 UV-inactivated HSV-l.KOS for 3 days. The

supernatant was collected and analyzed by ELISA for INF-y,IL-4, and IL-2. In brief,

supematants were incubated in duplicate, at varying dilutions in flat-bottomed 96-well
plates(Immulon 4, Baxter, McGaw Park, IL) precoated with anti-cytokine antibodies (rat
anti-IL-4, IFN-y and IL-2, Pharmingen, San Diego, CA)for 4 hours. Standards consisted
of recombinant murine IL-4(Collaborative Biomedical, Bedford, MA),recombinant

murine IFN-y(Genzyme,Cambridge, MA)and recombinant IL-2(Pharmingen, San

Diego, CA). All washes consisted of PBS/0.05% Tween 20. The appropriate secondary
biotinylated anti-cytokine antibodies(Pharmingen, San Diego, CA)were added and
incubated for 45 minutes, followed by incubation with peroxidase-conjugated anti-biotin

antibody (Vector Laboratories, Burlingame, CA)for 30 minutes. Color detection was

developed using ABTS (Sigma Chemical, St. Louis, MO)and plates were read at 405 nm
absorbance in an ELISA reader. Equal numbers of cells restimulated with Con A,or
without restimulation served as positive and negative controls, respectively.

Cvtotoxicitv assays

On day 14 after immunization, splenocytes were restimulated in vitro for 5 days
with UV-inactivated HSV-l.KOS at m.o.i = 1.5, and cytotoxicity assays were performed

exactly as described previously K EMT-6 cells (H-2'^ mammary adenocarcinoma cells),
EL-4 cells (H-2''lymphoma)infected with m.o.i = 5 of HSV-l.KOS for 4 h. were used as

the syngeneic and allogenic targets. EMT-6 cells without viral infection was used as the
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mock control. 2 x 10® of the target cells in 500 ul RPMI1640(Gibco, Gaithersburg,

MD)were labeled with 100 uCi of ®'Cr for 90 minutes at 37°C. After washing three
times, 10'* labeled target cells and serial dilutions of effector cells at effector; target ratios
of 100:1 to 6.25;1 were incubated in 200 ul of RPMI 1640 with 10% heat-inactivated

PCS in 96-well V-bottom plates. The plates were centrifuged at 500 g for 3 minutes and
incubated at 37°C and 5% CO2 for 4 hours. The supematant fluid (100 ul) was collected

to measure radioactivity, and the specific cytotoxic activity was determined using the
formula:

experimental release - spontaneous release

% specific release = —"

~

x 100

total release - spontaneous release

Depletion of IFN-y in BALB/c nu/nu mice

mAb against IFN-y was purified from R4-6A2(ATCC,HB170) hybridoma
ascites. The determination of depletion dose was followed by the method provided by
Smith et al. ^4. An initial dose of 1 mg antibody was given i.p. to the 3-4 weeks old

BALB/c nu/nu mice the day before viral challenge, and 0.5 mg were given every other
day after challenge.

Adoptive transfer experiments

On day 14 post-immunization, spleens were collected and single cell suspensions

were prepared. T cells were enriched by nylon wool column fractionation. The eluted
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cell population contained more than 80% CDs"^ cells as measured by flow cytometric

analysis(FACscan,Becton Dickinson, Franklin Lakes, NJ). Enriched T cells(2 x 10
cells in 200 ul of HBSS)were then injected i.v. slowly into GKO,BALB/c nu/nu and

BALB/c nu/nu with IFN-y depleted recipients. Twenty-four hours after adoptive transfer,
the recipient mice were infected with HSV-1.17 as described above.

Statistical analyses

Student t-test (unpaired, two tails) was used where applicable.

Results

Susceptibility to HSV infection in GKO mice

In order to compare the susceptibility of mice with or without IFN-y to HSV
cutaneous infection, GKO and wildtype(BALB/c) mice were infected with various does
of HSV-1,strain 17. As shown in Table 2-1, the susceptibility of GKO mice to HSV
cutaneous infection was increased. This heightened susceptibility detectable was in two

ways. Firstly, the establishment of visible lesions was achieved with 10-fold less virus
than that necessary to cause the zoster lesions in BALB/c mice. Secondly, when animals
were infected with 10'^ PFU of virus, lesions developed more rapidly in GKO animals

(Fig 2-la and b), who succumbed to encephalitis and died 3 days sooner than did control
mice. In addition, the cutaneous lesions that occurred in GKO mice appeared to represent

the combined results of sustained cutaneous replication at the site of infection, with

subsequent superimposed wounds of zosterification.

Nature of HSV specific immune responses in GKO mice

Next, to address the issue whether GKO mice could develop HSV-specific

immune responses comparable to BALB/c mice, the transgenic mice were immunized on
two occasions with a nonvirulent strain of virus. The first dose was UV-inactivated HSV-

1-KOS, and the second dose was live HSV-l-KOS at 2 x 10^ PFU/mouse by intradermal
injection. Two weeks after the immunization, animals were tested for humoral and T cell
immunity to HSV. As was to be expected, HSV-specific proliferative responses, and
secondary restimulated CTL responses were similar between GKO and wildtype mice
(Table 2-2). Regarding antibody, total IgG was at the same level in the two groups. The
ratio between IgG2a to IgGl differed between GKO and wt animals. Levels of IgG2a
were lower in GKO mice (approximately 3-fold), and IgGl antibody levels were higher.
The ratio of IgG2a to IgGl in GKO and wt was 1.3 and 8.1 respectively (Table 2-3).
GKO mice also slightly increased IL-4 production after immunization with HSV (Table
2-4).

Immunity to HSV challenge in GKO mice

Following immunization of GKO mice, they became solidly immune to HSV
challenge even when exposed to 500ID50(data not shown). To further investigate the
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role of IFN-yin T cell-mediated protection against HSV zosteriform challenge, splenic T
cells from immunized GKO mice were transferred intravenously to naive B ALB/c mice,

who were protected against zosteriform challenge (Table 2-5). To better

comprehend the nature and effectiveness of the induced immunity, an adoptive transfer
experiment was performed using nude (athymic nu/nu) mice. Nude mouse recipients, in
the absence of adoptive protection produce readily detectable zosteriform lesion (Fig. 22a). However, as is evident in Fig. 2-3b, T cells from both GKO immune and wildtype
irmnune animals provided protection from zosteriform challenge. To exclude the

contribution of IFN-y produced by the recipients of the adoptive transfer, experiments
were done in which animals were given GKO immune T cells to untreated animals as

well as animals additionally given neutralizing anti-IFN-y mAb. No differences in
protection were observed between the two groups.

Discussion

Removal of herpes simplex virus (HSV)-infected cells from peripheral sites such

as the skin is mainly an activity of T cells, particularly the CD4"^ T subset

Such

cells orchestrate an inflammatory response with interferon gamma(IFN-y) appearing to

play the essential role in viral clearance. In accordance with this hypothesis, this study
showed that infection of B ALB/c background mice expressing the knockout phenotype

for IFN-y(GKO mice) are significantly more susceptible to the development of cutaneous
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zosteriform lesions than are wildtype. However,following HSV immunization, GKO

mice become solidly immune to the development of zosteriform lesions. In addition, the
transfer of T cells from immune GKO mice to nude mice recipients renders the nude mice
resistant to zosteriform lesions.

From results of studies using specific mAb to IFN-y and more recently, the GKO
mouse,it is evident that susceptibility to several pathogens is remarkably increased,
whereas resistance to others seems unchanged. Notable examples of the former are
Mvcobacterium tuberculosis and Listeria monocvtogenes 5- 8- 12- 11 whereas influenza and

Semliki Forest virus are examples where susceptibility appears unchanged

Bouley

and Russell noted previously that following ocular infection of GKO mice, virus usually
spread beyond the orbit, a feature that also occurs in T cell-deficient mice, but not
immunocompetent animals 2.21. in the experiments reported in this study, animals were
infected intracutaneously with virus, a procedure which in immunocompetent mice results

in a brief period of cutaneous replication, followed by spread via the sensory nerves to the
dorsal root ganglia. At this site, virus replicates and disseminates back along the sensory
nerves to be released throughout the neurodermatomes producing what is termed a
zosteriform lesion 23. We favor this model because virus dissemination to the skin via

the nervous system, mimics what occurs in herpes recrudescence in man,the most

common clinical expression of HSV infection 26. GKO mice developed more severe and

rapid lesions upon HSV zosteriform challenge compared to wildtype mice, especially the
early signs which included sustained cutaneous replication vesicles. This may indicate
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impaired innate defense mechanisms in the absence of IFN-7.

Regarding the nature of immunity induced by HSV immunization, GKO mice are

fully capable of generating cellular and humoral immune responses similar to wildtype
mice, as has been observed by others with other agents ^5 . The slight differences were

found in the IgG isotypes, and IL-4 production, in which GKO mice produced more IgGl
and IL-4, whereas BALB/c mice produced more IgG2a and less IL-4. The explanation for
this observation might be that IFN-y inhibits IL-4 production and blocks the ability of B
cells to respond to IL-4, thereby inhibiting the Ig class switch
Manickan et al.

have previously shown that if splenic immune lymphocytes

were fractionated into 004"" and CD8"^ subfractions, protection was only achieved with

the CD4^ fraction. Studies from other groups have implicated EFN-y in mediating the

protection against HSV cutaneous infection ^4. However,the results from adoptive
transferring experiments using immune GKO T cells as donors showed that the absence
of IFN-y does not alter the protection provided by immune T cells. Multiple pathways
may be involved in T cell-mediated viral clearance.

The experiments in this study have two notable implications. Firstly, immunity to
the cutaneous infection of HSV can be transferred perfectly well by T cells which lack the

ability to produce fFN-y. Accordingly,the data do not support the previously held

viewpoint that T cells protect against HSV principally by releasing IFN-y 24. The assays
used to arrive at this conclusion principally measure CD4"^ T cells

^2, but the model

may be germane to what is occurring in man with HSV infection. In man, CDd"^ T cell
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parameters of immunity appear far more prominent than do CDS"^ T cell responses 22.
The second notable implication of our results is that mice lacking the ability to produce

IFN-y are indeed more susceptible to infection. Since T cells of GKO mice appear to
function effectively, such results presumably imply that the effectiveness of the other

aspects of immunity, such as the innate cellular functions of NK cells, are likely
compromised. Certainly in older studies, a vital role for NK cell function was shown in
many ways '5, and NK cells are considered to be dependent on IFN-y for their normal
function

IFN-y is also known to effect macrophage function, for example, up-

regulating potential antiviral activities such as nitric oxide and TNF-a production '3- 1427' 6, Indeed, recent studies have claimed that NO may act to inhibit HSV replication 6,
although we have not been able to confirm this observation.
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Table 2-1. Comparison of susceptibility between GKO and wt mice to cutaneous HSV-1.17 infection

Dose

5 X 10^ PFU

1 X 10'PFU

5 X 10' PFU

1 X 10" PFU

GKO

wt

2/4

0/4

(1.1,0.0)

(0,0.0,0)

3/4

0/4

(1.1.1.0)

(0,0,0,0)

3/4

0/4

(2,1,1.0)

(0.0.0.0)

4/4

4/4

(2.3,3,2)

(1.1.1.1)

GKO
2/4

(d'.d.O.O)
3/4

(2,d.2.0)
4/4

(d.2,3,1)
4/4

(d.d.d.3)

Day 11

Day 9

Day 7

Day 5

wt

0/4

(0.0,0.0)
1/4

GKO
2/4

(d.d.0,0)
4/4

GKO

wt

2/4

0/4

(0.0.0,0)

(d.d.O.O)

0/4

(0.0.0.0)

4/4

0/4

(d.d.3.d)

(0.0.0.0)

1/4

(2.0.0.0)

wt

(2,0,0.0)

(d.d.d,2)

2/4

4/4

2/4

4/4

2/4

(d,d.d.3)

(3.3,0.0)

(d.d.d.d)

(4.4.0.0)

(1.2.0,0)
4/4

(1.2.3.3)

4/4

(d.d.d.d)

4/4

4/4

4/4

(3.3.4.4)

(d.d.d.d)

(d.d.d.d)

The number of mice which developed skin lesion and their clinical scores were recorded 5 days after viral infection.

Except Day 9, and Day 11 of 10'* PFU infection groups, the mean of clinical scores have significant differences (p<0.001;
students' T-test) between GKO and wt mice. The values in the parenthesis indicate the clinical severity of the lesion from
each mice. The table represents one of the 3 experiments conducted and yielded comparable results.
d: death; GKO = Interferon gamma gene knockout mice; wt = wild type

Table 2-2. CMl induced by UV inactivated HSV-l.KOS in GKO and wt mice

Ag-specific CTL''

Ag-specific proliferation®

E:T Ratio

R:S Ratio
10:1
GKO
wt

5:1

2.5:1

100:1

25:1

6.25:1

92000 45000

20000

38.52±2.08

23.33±0.85

16.85±4.43

90000 44000

22000

41.57+1.43

24.63±0.98

17.22±2.01

The proliferation of Ag-specific spleen cells from HSV-1-immunized GKO and wt

mice were assayed for incorporation of[^H]thymidine 72 hours after simulated with xirradiated UV-inactivated HSV-l-KOS-infected syngeneic mouse spleen cells. The units

are expressed in cpm (count per minute). Standard deviation (SD)was less than 2000
cpm in each of the group. Without infected stimulators, both GKO and wt spleen cells

incorporated [^H] thymidine less than 1500 cpm. R: responders, S: stimulators.

'' The Ag-specific CTL activity was measured by 4 hr ^'Cr release assay. The data shown
in the table reflect the specific lysis(%)of a syngeneic HSV-1-infected target cell line
(EMT-6). There were no significant differences between GKO and wt mice at all three

E:T ratios (p>0.1 by student-t test). The specific lysis of allogenic targets(EL-4)and
mock targets (uninfected EMT-6) was less than 5%,and 2% respectively. E: effectors, T:
targets.

HSV-l.KOS immunization ^
IgG2a:IgGl

Total IgG
Ug/ml

IgG2a
ug/ml

IgGl
ug/ml

wt

23 ± 1.4

8.0 ± 1.1

1.0 + 0.3

8.1

GKO

31 ±2.1

2.9 ± 0.4

2.3 ±0.3

1.3

The levels of HSV-1 specific IgG and isotypes in preimmune GKO and wt mice were
undetectable.
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Table 2-4. Cvtokine production in GKO and wt mice
with HSV-l.KOS immunization^

cytokines

wt

GKO

IL-4

115 ± 20 pg/ml

320 + 90 pg/ml

INF-y

230 + 75 ng/ml

ND

IL-2

2.6 + 0.9 ng/ml

6.8 ± 1.9 ng/ml

In the supematants from cells without viral restimulation, all the cytokines were
undetectahle. ND: not detectable.
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Table 2-5. Adoptive transfer HSV-1 protection to naive
GKO and wt recipients

Donors

gko/HSV"

Recipients

80

GKO

100

wt

wt/HSV

100

GKO

100

wt

gko/naive

wt/naive

% of protection
'

GKO

0

wt

0

GKO

0

wt

0

Protection was defined as clinical lesion scores no more than 1 during two weeks after
challenge.

GKO or wt mice immunized with UV-HSV-1(KOS)(2 x lO'FPU)on days 0, and 2 x
10^ FPU live virus on day 7. Splenocytes from immune or naive control mice were

collected on day 14 and adoptively transferred(2 x 10^ cells) to the recipients described.
There were five recipients in each group.
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Fig. 2-1 Comparison of susceptibility to cutaneous HSV infection between
GKO and BALB/c mice

a.

A 4-5 week old female naive GKO mouse was infected with 1x10'* pfu of HSV-1
strain 17 in the left mid-flank region. A significant skin lesion could was observed at the
viral inoculation site 4 days post infection.

b.

A 4-5 week old female naive BALB/c mouse was infected with 1x10"* pfu of
HSV-1 strain 17 in the left mid-flank region. No significant skin lesion were observed at
the viral inoculation site 4 days post-infection.
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Fig. 2-2 HSV zosteriform lesion in nude mice
a.

A 4-5 weeks old female nude(H-2^) mouse was infected with 1 x lO'^ pfu of HSV1 strain 17 in the left mid-flank region. Ten days post-infection a band-like skin lesion
formed. The same lesion was also observed in nude mice adoptively transferred with T
cells from naive GKO or BALB/c mice.

b.

A 4-5 week old female nude (H-2'^) mouse was adoptively transferred with T cells
from HSV-immune GKO mice. Twenty-four hours post-transferring, the mouse was

challenged with 1 x 10"^ pfu HSV-1 stain 17 in the left mid-flank region. Ten days after
viral infection, no lesions occurred. Nude mice transferred with T cells from HSV-

immune BALB/c mice also failed to develop skin lesions.
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Fig. 2-3 Adoptive transfer of HSV-1 protection

Adoptive transfer of HSV-1 protection to naive nu/nu mice. Each mouse was

infected with 10"^ PFU HSV-1.17 24 hrs after receiving cells i.v. Five mice were included
in each group. There were no significant differences in clinical scores between the
recipients with wt donor cells and those with GKO donor cells.

b.

Adoptive transfer of HSV-1 protection to nude mice with mAb anti-IFN-y
treatment one day prior to adoptive transferring (1 mg/mouse/day i.p.) and every other

day after (0.5mg/mouse/day i.p.). Each mouse was infected with 10"^ PFU HSV-1.17 24
hours after receiving cells i.v.. Five mice were included in each group. There were no
significant differences in the clinical scores between the recipients with wt donor cells
and those with GKO donor cells.
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a.

4.5

4-

wt/HSV
GKO/HSV

3.5

naive wt

naive GKO

2.5

1.5

0.5

day?

days

days

days

day 10

day 9

day 10

days post challenge

b.

Wt/HSV

GKO/HSV
3.5

naive wt

naive GKO

2.5

1.5

0.5

day 7

day 8

days post challenge
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Part III

A Novel Approach to DNA Vaccines:

Epitope Minigene Immunization in HSV Model

108

Rationale and Objectives

Effective vaccines are not currently available for many agents including HSV.

Multiple reasons exist and include a virus-host relationship that for long periods fails to
elicit interference by the immune system, and a lack of acceptable immunogens to

effectively induce protective immunity. Indeed, one vaccine design strategy is to

selectively expand the immune components which provide a protective role and diminish
activities which are potentially harmful. In the HSV mouse model, it is necessary to
maximize CDS"^ T cells and 004^^ Thl cell subset responses because these components

are crucial for prompt and effective viral clearance

To achieve this "designer

immunity",DNA vaccines which encode the minimal epitopes of HSV may prove
convenient and effective.

As outlined in this part of the dissertation, the primary research objectives were:

(1)to engineer a minigene cassette containing CDS"^, CD4"^ T cells as well as B cell
epitopes of HSV-1 into a mammalian expression plasmid DNA,
(2)to examine the epitope-specific immune responses induced by the minigene construct
following immunization of mice, and

(3)to determine the protective nature of the immunity induced by the minigene DNA.
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Introduction

Vaccinology is the pursuit of immunogens to provide long-term protective

immunity with no detrimental effects. Synthetic peptides containing minimal epitopes

represent an attractive vaccine prospect since these might be non-toxic and,if composed
of appropriate components, could tailor immunity in a desired direction ("designer"
iimnunity). However,even with sophisticated delivery systems and adjuvants, peptide
vaccines usually lack acceptable immunogenicity

The observation that plasmid DNA

encoding viral proteins elicited protective immunity opened a new chapter in
vaccinology

. DNA vaccines induce broad spectrum immune responses similar to

those obtained with live virus, arousing hope that this approach represents a practical

alternative to attenuated vaccines ^

DNA encoding numerous viral proteins have been

evaluated for their potential use as vaccines, and their license for use in man and animals

is expected soon. However,it is not clear if DNA vaccines can be used to encode
minimal epitopes and thereby engender component-selective immunity. In this report, we

investigated the immunogenicity of plasmid DNA encoding small peptides recognized as
epitopes of herpes simplex virus(HSV)in the mouse. A plasmid was designed to

encoded two small peptides(gB 498-505 and ICP27 448-456) recognized as targets for CTL,

as well as a larger peptide (1-23 of glycoprotein D)known to stimulate both antibody
2 9 27

production and a CD4+ T cell response in several mouse strains '' .
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The plasmid DNA minigene construct was immunogenic especially for CTL induction.
Antibody and €04"^ T cell responses occurred, but antibody responses remained modest.
Animals immunized with the plasmid were immune to subsequent viral challenge at least

against exposure to a low dose of virulent virus. The potential value of DNA encoding
minimal epitopes to manipulate individual components of immunity is briefly discussed.

Materials and Methods

Mice

Three to four week old female BALB/c and C57BL/6 mice were purchased from

Harlan Sprague Dawley,Indianapolis, IN. All investigations followed the guidelines of
the Committee on the Care of Laboratory Animal Resources, Commission on Life
Sciences, National Research Council.

Virus

HSV-1 strain 17 and KOS were grown on Vero cell monolayers and stored
at -80°C until use.

Minigene Synthesis

The oligonucleotides were purchased from Gibco/BRL Life Technologies,

Gaithersburg, MD. Three ng of oligo 1 (5'GGG AAG CTT GAG GAA ACA ACT ATG
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ATC AAG ACC TCC TCC ATC GAG TTC GCC CGG CTG GAG TTT ACG TAG

GTG GGG GAG ATG GAG TAG GGG AGG GTT GGT GTG GGG GTG GGA 3') and

oligo 2(5' GGG GAT GGG GGG AAG GTG TTT GGG GGG AAA GGG ATT GGG
GTG GGG GAT GTT GAG AGA GGG ATG GGG GAA GGG ATA TTT GAT GTT
CTG TGG GAG GGG GAG AGG AAG GGT 3') each were placed in a reaction mix

containing 0.5 mM MgGl2,0.2mM dNTPs, 1 x UITma™ Buffer(Perkin-Elmer, Foster
Gity, GA)and subjected to 10 cycles of overlap (underlined sequence) extension using
UITma™ DNA polymerase (Perkin-Elmer, Foster Gity, GA). The overlap extension
conditions were 94°G for 2 mins, 55°G for 1 min, and 72°G for 1.5 mins. Following

overlap extension, 5 ul of the reaction was removed and subjected to PGR (34 cycles)

using UITma™ polymerase with the two synthesized primers, KA (5' GGG AGA TGT
GGG AAG GTT GAG 3'), and KB (5' GGG GGT AGG GGG GAT GGG GGG 3'),

which are complementary to the ends for the overlap products. Gonditions for this PGR
were same as mentioned above. The resulting products were digested with Hind III

(Promega, Madison, WI)and BamH I(Promega, Madison, WI), and then purified from
2% agarose gels using the Geneclean II kit(Bio 101,Inc, Vista, GA). The purified

minigene fragment was cloned into the multiple cloning site of pcDNA3.1 mammalian
expression plasmid (Invitrogen, San Diego, GA)named as pcMini. Sequencing was

performed by University of Tennessee Knoxville DNA Sequencing Laboratory. The

sequencing data revealed an intact 207 bp insert correlating to the synthesized oligo
sequences containing oligonucleotides encoding HSV-1 gB 494-509> IGP27 444.450 and
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gDi.23 (Fig. 3-1).

DNA preparation

The plasmid DNA was prepared by using Promega Maxiprep Column (Promega,
Madison, WI). OD260(Optical Density) was used to determine the DNA concentration.
The OD260/OD280 ratio of the samples was between 1.78-1.82, and no significant RNA or

genomic DNA contamination was observed by electrophoresis. The samples were also
subjected to Limulus amebocyte lysate test (Charles River Endosafe, Charleston, SC), and
the endotoxin level was less than 0.06 EU (endotoxin unit).

Expression of minigene

Transformed human embryonal kidney cells, 293 cells(ATCC,Rockville, MD)
were transient transfected with pcMini DNA or pc DNA3.1 using LipofectAMINE

(Gibco, Gaithersburg, MD)following the manufacturer's protocol. Forty-eight hours

later, total RNA were isolated from a million transfected cells and treated with 3 units of

RQl DNAase(Promega, Madison, WI)at 37°C for 30 mins. In addition, 300 mg of
mouse tibialis muscle was homogenized in Tri-Reagent(Molecular Research Center, Inc.,
Cincinnati, OH)48 hours after the pcMini or pc DNA3.1 injection and analyzed for

pcMini expression. Total RNA was isolated and treated with DNAase the same way as
the transfected cells. Five to ten ug of the total RNA were then reverse transcribed in a

20 ul reaction using 30 pmoles of oligo dT18, and AMV reverse transcriptase according
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to the manufacturer's protocol(Promega, Madison, WI). The cDNA was diluted 1:2 in
sterile distilled water (total 50 ul)and 5 ul was used for PGR. Aliquots of cDNA were

amplified in a 25 ul reaction mixture containing 0.5 mM MgCla,0.2 mM of each dNTP
and approximately one unit of Taq polymerase (Promega, Madison, WI). Primers used
were from internal sequences of the minigene, KD (5' ATG ATC AAG ACC ACC TCC
TCC 3') and KE(5' CGG AGG GTC TIT GCC GCG AAA 3'). Amplication using

these primers results in a 170 bp product. PGR was performed for 34 cycles at 94°G for
1.5 mins,55°G for 1 min, and 72°G for 2 mins. Reaction products were analyzed on 2%
agarose gels and stained for visualization with ethidium bromide.

Seventy-two hours after transfection or injection with the DNA,2 million 293
cells or 300 mg of mouse muscle tissues were lysed or homogenized in 500 ul of
radioimmunoprecipitation assay (RIPA)buffer containing 1% NP40, 1% sodium
deoxycholate, 1% triton X-100 and 100 uM of each the protease inhibitors

(phenylmethylsulfonyl fluoride, aprotinin, and leupetin). The resulting total cell lysate
were blotted on nitrocellulose membrane(Micron Separations Inc. Westborough, MA)

pre-soaked with 100% methanol and electroblot transferring buffer(39 mM glycine,48
mM Tris Base,0.037% SDS,20% methanol). The membrane was then probed with mAb

against HSV glycoprotein D(Glone#991,BioDesign, Kennebunk, ME)and visualized by
a subsequent incubation with alkaline phosphatase (AP)-conjugated anti-mouse IgG

(Sigma, St. Louis, MO). Golor development was performed using AP color reagent(BioRad laboratories, Hercules, GA).
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Immunization

100 ug of pcMini or pcDNAS.l plasmid DNA in 100 ul of Hanks' Balanced Salt
Solution(HBSS)(Gibco, Gaithersburg, MD)was injected into the tibialis muscle of the
mice at day 0. The mice were boosted with the same doses of DNA on day 14. In the

prime-boost experiment, after a single-dose injection, 10^ plaque-forming units(pfu) of
recombinant vaccinia virus expressing HSV-gD was administered intramuscularly at day

28. 10^ pfu of live HSV-1 KOS were given intramuscularly to the mice as a positive
control.

Antibody detection

Individual serum samples collected from immunized mice were assayed for gD i.

23 or gD-specific IgG by ELISA. The ELISA plates were coated with 100 ul of carbonate
buffer(40 mM NaHCOs,20 mM Na2C03)containing 30 ug/ml of gDi.23 peptide

(Medical Center, University of Tennessee Knoxville) or 2 ug/ml of HSV-1 gD protein

(kindly provided by Phillip Berman, Genentech, South San Francisco, CA)at 4°C

overnight. After blocking with 3% non-fat milk in PBS for 1 hr at 37°C and rinsing three
times with phosphate-buffered saline (PBS)/Tween 20(0.05%) solution, serum samples
were added to each well with double dilution starting at 1:20 or 1:50 in PBS. The plates
were then incubated at 37°C for 2 hours and rinsed with PBS-Tween throughly. Goat

anti-mouse IgG-horseradish peroxidase (HRP)-conjugated (Southern Biotechnology,

Birmingham, AL)was then used at 1:2000 dilution for 30 mins of incubation at 37°C.
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ABTS solution (llmg 2,2'-azinobis (3-ethylbenzthiazoIine-6-sulfonic acid, in 25 ml of
0.1 M citric acid, 25 ml of 0.1 M sodium phosphate and 10 ul of 30% hydrogen peroxide)
was used for color development. OD 405 was measured by automated ELISA plate

reader (Spectra Max 340, Molecular Devices, Sunnyvale, CA). The concentration of Ab
was determined according to the standard curve of mouse IgG in a sandwich ELISA.

Lvmphoproliferation assays

Immune spleen cells were collected and restimulated in vitro with various ratios
of stimulator cells for four days in RPMI medium (Sigma, St. Louis, MO)containing
10% bovine fetal serum, 100 lU/ml of penicillin, 100 ug/ml of streptomycin, 2mM L-

glutamine,5 x lO'^mM 2-mercaptoethanol,25mM HEPES,0.2% NaHCOs pH=7.2.
Stimulator cells were x-irradiated naive syngeneic spleen cells pulsed with 30ug/million

cells of gDi.23 peptide (University of Tennessee Medical Center, Knoxville, TN), or

other irrelevant peptides(HA 303-313, University of Tennessee Medical Center, Knoxville,
TN). In some experiments, the irradiated spleen cells were infected with UV-inactivated
vaccinia virus expressing glycoprotein D of HSV (VgD)or HSV at multiplicity of
infection (m.o.i.) of 2 for four hours. Responder to stimulator ratios ranged from 50:1 to

1.6:1. Eighteen- hours before the harvest,[^H] TdR (Thymidine,ICN Radiochemicals,
Costa Mesa, CA)at a concentration of 1 uCi/well was. After harvesting, the

radioactivity in pelleted cells was measured with a beta scintillation counter (Inotech,

Lansing, MI). Results were expressed as stimulation index:(counts per minute(cpm)of
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responders with antigen treated stimulators/ cpm of responders with naive stimulators).
Responders cultured in media containing 1 ug/ml of concanavalin A (ConA) were used
as positive controls for the lymphoproliferation assay.

Cvtokine Assay

Spleen cells from immunized mice were restimulated with gDi.23 peptide
(30ug/million cells)-pulsed syngeneic APCs at ratio of 50:1 for 5 days. The supematants

were assayed for IL-2,IFN-y, and IL-4 production by standard ELISA protocol from the
manufacturers. All the antibodies were from Pharmingen, San Diego, CA.

Cvtotoxic T cell Assays

Splenocytes (effector cells) collected from immunized mice were measured for the

presence of antigen-specific MHC-restricted CTLs. The effectors were restimulated in
vitro with UV-inactivated HSV-1 KOS (m.o.i. = 1.5) in limiting dilution assay buffer(Ix

NCTC 109, 0.4x RPMI-1640, 10% heat inactivated bovine fetal serum, 10 mM sodium

pyruvate, 100 lU/ml of penicillin, 100 ug/ml of streptomycin, 2mM L-glutamine,
5 X lO'^mM 2-mercaptoethanol,25mM HEPES,0.2% NaHCOs pH=7.2. Ix MEM
essential amino acids, Ix EME non-essential amino acids, and 1 x MEM vitamin solution

(Gibco, Gaithersburg, MD),0.08% insulin, 0.12% oxaloacetic acid) and incubated at

37°C for 5 days. The effector cells were then mixed at various ratio with Cr^' labeled

target cells for 4 hours. The targets included EL-4(H-2'') and EMT-6 (H-2'*) cells pulsed
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with 100 ug/million cells of gB 498-505(SSIEFARL)or ICP-27 448-456(DYATLGVGV)

peptide, or pcMini or pcDNAS.l transient transfected in EMT-6 and EL-4 cells, or live
HSV-infected (m.o.i. = 5)EMT-6 and EL-4 cells. The supematants were taken after the
incubation for measurement of radioactivity. The results were expressed as specific lysis

=(cpm of sample release - cpm of spontaneous release)/(cpm of total release - cpm of
spontaneous release).

Viral challenge

Mice were challenged with HSV as described elsewhere

. Briefly, the left

flank of mice was shaved with a hair clipper and a chemical depilator. The mice were

then anesthetized using metofane (Mallinckrodt Veterinary, Inc. Mundelein,IL), and a

total of 20 scarifications were made in an approximately 4-mm^ area. 1x10'* PEU (IOID50
of BALB/c mice, 10 times the viral dose causing cutaneous lesions in 50% of the infected

mice) of HSV in 10 ul HBSS,or Ix lO^PFU (IOID50 of C57BL/6 mice) were added and
gently massaged into the scarification area. Animals were inspected daily for the
development of zosteriform ipsilateral lesions, general behavioral changes, encephalitis,
and mortality. The severity of the erosion and ulceration of the local lesion were scored
as follows: 1+ = vesicle formation; 2+ = local erosion and ulceration of the local lesion;

3-f = mild to moderate ulceration, and 4+ = severe ulceration, hind limb paralysis, and

encephalitis. The moribund animals were euthanatized.
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Statistics

Unpaired, 2-tail student-t test was used where applicable.

Results

Expression of minigene

The minigene encoding multiple epitopes of HSV (gB 494-509. ICP27 444-460. and

gD 1-23) was constructed by overlapping PGR and cloned into pcDNAS.l plasmid vector.
In order to confirm expression of the minigene, RT-PCR using internal primers for the

minigene and dot-blot analysis with mAb against HSV-gD protein were performed on
DNA-transfected cells or DNA-injected muscle tissues.

The RT-PCR of the isolated total RNA from pcMini or pcDNAS.l-transfected

293 cells and injected muscles is presented in Fig. 3-2a. A 170 bp band can be seen in
the lanes of pcMini-transfected cells and injected tissue samples, indicating that the
mRNA of the minigene is expressed. To eliminate plasmid DNA contamination in the

samples, all the RNAs were subjected to DNAase treatment. The DNA-free RNA was
also subjected to RT-PCR to identify the minigene fragment, which were all negative on
the gel (Fig. 3-2a).

For protein expression, cell lysates from DNA-transfected cells or injected
muscles were immobilized on nitrocellulose membranes. Both cell lysates from pcMini-
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transfected or injected samples reacted with mouse mAb against HSV-1 gD as shown in
Fig. 3-2b. In contrast, the lysate from pcDNA3.1 treated samples did not.
In designing the minigene cassette, engineering to enhance expression became a
major concern. Since earlier studies by Kozak have shown that consensus sequences
12

upstream from the start site of transcription regulate gene expression ,these so-called
"Kozak sequences" were introduced to enhance the gene transcription in many expression
systems

. Unlike the synthetic gene, most cDNAs used in DNA vaccines

naturally contain such consensus sequences. To compensate this, a strong Kozak

sequence was therefore encoded upstream of the minigene start codon. This sequence
enhanced mRNA and protein expression compared to a non-Kozak minigene construct
(data not shown).

Humoral responses induced by minigene

gD 1-23 contains strong epitopes for induction of antibodies in both BALB/c and
C57BL/6 mice

The minigene was designed to encode this epitope to generate antibody

responses. After two administrations with plasmid DNA,the gDi.23-specific antibody
was generated in both BALB/c and C57BL/6 mice as shown in Table 3-1. Compared to
live HSV immunizations, the antibody levels were 5-20-fold less; however, the titers

were significantly higher (200-fold) than that seen in vector control animals. The peak
antibody level was seen at 4-6 weeks after immunization, and decreased to undetectable
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levels at about 10 weeks. This contrasts with live virus infection, where antibody levels
are maintained at high levels for prolonged periods.
In order to determine if the minigene plasmid primed animals for a subsequent

prominent antibody response, the immune responses of animals primed with minigene or
control plasmid and subsequently challenged with recombinant vaccinia encoding gD
(VgD)were investigated

Within a week after the VgD boosting, the pcMini

sensitized mice serum anti-gD specific antibody was about 5 fold higher (statistically

significant p<0.005) than control vector-primed mice (Table 3-2). This significant
antibody enhancement upon secondary stimulation did not occur when pcMini was used
as a boost, since multiple immunization with the DNA did not significantly increase the
antibody titers (data not shown).

Cellular responses induced by minigene

The three epitopes encoded in the minigene were expected to elicit good cellular

immune responses. The gB 498-505 epitope induces CTL activity in C57BL/6 mice ; the

ICP27 448-456 peptide represents a CTL epitope in BALB/c mice 2, and gD 19-23 is a strong
CD4''T cell epitope 11. To examine whether these epitopes, placed together in a

minigene,could be recognized by T cells, in vitro lymphoproliferation and CTL assays

were performed following the DNA immunization of BALB/c and C57BL/6 mice.
Spleen cells from pcMini-immunized mice were tested for proliferative responses
to gD 1-23 peptide or UV-inactivated HSV in vitro. The
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[TdR]incorporation assays

indicated that the stimulation index increased significantly in pcMini DNA immunized

mice compared to those receiving the vector (Fig. 3-3a). This lymphoproliferative

response was peptide-specific, since irrelevant peptide (influenza HA 303-3i3)-pulsed APC
did not stimulate proliferation (Fig. 3-3a). Proliferative cells also had enhanced

expression of IFN-y and IL-2 upon in vitro restimulation (Table 3-4). Although present,
this stimulation was approximately 50% less than in HSV immunized mice. Further

evidence that the minigene was immunogenic for T cell proliferative response came from

experiments in which animals were immunized with pcMini, and 30 days later boosted
with recombinant vaccinia virus expressing gD. As shown in Fig. 3-3b, the proliferative

responses measured 7 days later were approximately 5-fold higher in the minigeneprimed animals compared to those given plasmid vector alone.
To examine the immunogenicity of two CTL epitopes, spleen cells from
immunized mice were restimulated in vitro with UV-inactivated HSV-l-KOS for 5 days.

The expanded populations were than assayed for CTL activity against a panel of targets,
which included both peptide- and virus- infected cells. In BALB/c mice, both HSV-and

pcMini-immunized splenocytes could recognize and lyse syngeneic target cells(EMT-6)
pulsed with ICP-27 444.452 peptide or infected with live HSV,but not the allogeneic
targets(EL-4)or syngeneic targets with gB 495-501 peptide. Similarly, in C57BL/6 mice,

HSV and pcMini primed splenocytes specifically killed the syngeneic target cells pulsed
with gB 495-501 peptide or infected with live HSV,not with ICP-27 444-452 peptide or
allogeneic targets. Interestingly, the level of killing exhibited by effectors from minigene122

immunized mice was similar to that of effectors from virus-infected mice when measured

against syngeneic peptide-sensitized targets. However,the two effector cell populations
showed marked differences when tested against virus-infected targets. Thus, the effectors

from minigene-immunized mice were inferior to those from virus-infected animals (Table
3-3).

In addition, EMT-6 cells transfected in vitro with pcMini DNA could be

recognized as CTL targets by the DNA-immunized BALB/c mice splenocytes. The
transfection of pcMini to EL-4 cells failed (could not detect mRNA and protein product
after transfection), therefore, this target was not included in the CTL assay. As a negative

control, the targets transfected with vector DNA could not be recognized by the CTLs.

Protection against HSV zosteriform challenge

The mouse zosteriform model using a challenge dose of IOID50 was used to

measure the protection against viral challenge after minigene immunization. All the mice
injected with the vector pcDNA3.1 developed skin lesions (10/10)(lesion score > 2+)
within 7-14 days post-viral challenge. However,4 out of 10 BALB/c mice and 6 out of
10 C57BL/6 mice were protected from developing lesions after pcMini-immunization
(Fig. 3-4a and 3-4b).

The protection was also reflected by the mortality of the infected mice. The

majority of the vector (pcDNA3.1)-treated mice,(8 out of 10) died from encephalitis
within two weeks after IOID50 viral challenge. However, only 2 out of 10 mice in both
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C57BL/6 and B ALB/c mice that received pcMini showed encephalitis. The results are
shown in Fig. 3-4a and 3-4b.

The protection from live HSV immunization is more solid than that induced by
pcMini. All the mice with viral immunization were able to resist low and high dose
challenge(up to 100ID50); however, the minigene-immunized mice failed to provide
protection against 100ID50 challenge (data not shown).

Discussion

In this study, a novel plasmid DNA vaccine approach was used to show that

multiple small peptides encoding T and B cell epitopes of HSV successfully induced

protective immunity in mice. Instead of using plasmid DNA to encode intact proteins, a
minigene construct was designed to encode small peptides of three HSV proteins. These

peptides represented HSV epitopes recognized either by T or B cells. Immunization with
this construct, which included two well-characterized CTL epitopes, induced robust CTL

responses which were of the same magnitude as those evident after live virus infection.
The minigene also included B cell and CD4''T cell recognized epitopes. Significant
€04"^ T cell responses were evident, although these were less than what occurred with
live virus infection. The minigene immunogens proved to be weak stimulators of

antibody production. However, animals were primed for notable responses to secondary
immunization with recombinant vaccinia virus encoding an HSV glycoprotein.
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The most notable responses evident following pcMini DNA immunization were

CTL. Animals were primed to generate peptide-specific secondary responses similar in

magnitude to those following live virus infection. From the MHC restriction pattern, the
CTL were assumed to be CDS'" T cells. The observation that pcMini DNA encoding a

small peptide was a potent CTL stimulus contrasts with what normally occurs when the
peptide itself in used for immunization

For such peptides to induce CTL,they usually

require special circumstances, such as high concentration, coupling to other proteins or
the use of powerful adjuvants, and special delivery vehicles

2' 20'25

. Thus, the pcMini

approach may prove to be a valuable means not only of achieving minimal epitope CTL
induction, but also to provide a way of identifying CTL immunogenic epitopes.

Although the minigene DNA induced excellent CTL responses as measured with

peptide specific targets, the responses were less impressive against virus-infected targets.
This discordance in activity of CTL measured against peptide and viral targets has been

noted in some other systems L In fact, CTL that kills peptide but not viral targets have
been considered as low affinity CTL and may,in fact, be inefficient when their function is
measured in vivo 23. Accordingly the plasmid DNA-encoding minigene approach may
have to be modified in some way to induce more functional CTL. This labortory is
attempting to achieve this objective.

The pcMini designed for these investigations encoded the 1-23 amino acids of gD,
a well-characterized fragment that contains at least two B cell recognizable epitopes and 1
or more CD4"'T cell epitopes 27. The 1-23 peptide is not considered to contain CTL
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epitopes, at least in H-2'' or H-2'^ mice

The minigene immunization did induce

lymphoproliferation and T cell cytokine release in both H-2''and H-2'' mice, but these
presumably CD4''T cell functions were lower than occurred after live virus infection.
The least impressive immune response induced was antibody production. Thus, despite

repeated immunizations, peptide-specific responses were far less than what occurred after
live virus infection. However,the pcMini immunization did prime animals for a

subsequent robust antibody response following secondary immunization with
recombinant vaccinia virus expressing gD protein. The observation that DNA

immunization may prime for subsequent elevated antibody responses upon heterologous
01

system inununization has been noted by others . A mechanistic explanation for such an
observations is not available, but it may relate to less efficient processing and

presentation of this peptide or perhaps destruction of APC by a concomitant CTL
response induced by the minigene 13 . in addition, investigations are undergoing to
determine if the coadministration or co-expression of adjuvant molecules will increase
the in vivo humoral immunogenicity of the minigene approach.

Finally, as regard the possible use of plasmid DNA encoding minigenes in
vaccinology, it was shown that immunized animals were resistant to systemic challenge
with virulent HSV. For this purpose, a model was used which likely measures the
function of both €04"" and CDS"T cell activity. In this mouse zosteriform model, control
of virus infection in the skin is considered as a 004"^^ T cell function

, and control of

virus dissemination to the CNS a CD8+ T cell function . As also observed with pcDNA
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encoding HSV proteins, protection against zosteriform challenge was evident, but only
against low-dose challenge

In contrast, live virus immunization, as well as

recombinant vaccinia virus expressing HSV proteins, protects against a substantial

challenge ^5. Accordingly all pcDNA immunization approaches may require further
modifications before they become serious candidates for use as practical vaccines.
In conclusion, the results from this study show that immunization with plasmid

DNA encoding minigenes represents a successful means to achieve epitope-specific
immunity. It could be that this approach might prove most useful to tailor immune

responses in situations where some necessary reactivity is missing, as some evidence
shows that this strategy could prove useful in treatment of certain cancers 4.
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Table 3-1 gPi.^^-specific antibodies induced by minigene immunization

live HSV

pcMini

pcDNAS.l

C57BU6

BALB/c

Immunogen

Expt 1

Expt. 2

Expt. 1

2306 ± 773

7293 ± 3805

2728 ± 968

Expt.2
3310± 1579

190 ±38*

261± 374

429 ± 209*

244 ± 139*

3±4='

2±3

Otl"

0±0*

®" Mice were immunized with various immunogens on day 0 and day 14. On day 28,
serum from individual mice was collected and assayed for gDi.23 specific antibody by
ELISA. Five mice were studied in each group. The data in the table are the mean

concentration of serum gDl-23 antibodies from individual mice ± standard deviation
(SD). The unit for the antibody concentration is ng/ml.

* Student-t test (unpaired, two-tail) show significant difference between pcMini and
pcDNAS.l immunized mice.

131

Table 3-2. VgD recalled responses in minigene primed mice

gD-specific serum Antibody (ng/ml)
dayS post boost

day 7post boost

boost

pre-boost

HSV

HBSS

4249 + 150

4668 ± 560

4756 ±458

HSV

VgD

4401±123

49147 ±2290

40316 ±2914

PCS

HBSS

<5

<5

PCS

VgD

<5

373 ±74*

Mini

HBSS

86 ±24

83 ±32

Mini

VgD

85 ±16

1710 ±249*

HBSS

VgD

<5

immunization

326 ±58

<5

568 ± 65**
125 ± 20
2290 ±321**
515±58

Mice were injected i.m. with various immunogens on day 0. Thirty days later,
recombinant vaccinia virus expressing glycoprotein D of HSV (VgD)or HBSS was

injected i.m. in the same mice. Serum samples from animals pre- and post- boost were
collected at different time points and assayed for gD-specific IgG by ELISA. The data are
the mean concentration of individual mice serum anti-gD IgG ± SD.

* On the 5th and ** 7th day post-boost with VgD,serum gD-specific antibody levels of

minigene immunized mice were significantly higher than those of pcDNA3.1-immunized
mice (unpaired two-tail student t-test p<0.005, n = 4).
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Table 3-3 Specific lysis(%)of epitope specific CTLs induced by pcMini DNA
Effectors
'

pcMini Imm.

Live HSV Imm.

Targets'*

BALB/c C57BU6

BALB/c

C57BU6

pcDNA3.1 Imm.
BALB/c

C57BU6

EMT-6/HSV'

40 ±8

4±2

15±5

3± 1

5±2

0±2

EMT-e/ICPl?"

34±5

0±1

30 ±7

3±4

0+ 4

2+ 3

EMT-6/gB'

3±1

2±2

0±2

0±3

2±2

4±3

EL-4/HSV'*

5 +4

38 ±5

0±1

12±4

2± 1

3±2

EL-4/ICP27''

5±2

2± 1

0±1

2±3

0+ 2

1±2

EL-4/gB'

1±2

52±7

2±1

55 ±8

3±1

3±2

35±4

4±3

28 ±5

0+ 3

8±2

5±3

0±2

1±3

5±2

4+ 3

7±5

2± 1

EMT-6/Mini'

EMT-6/pcDNA'

Mice were immunized with various immunogens on days 0 and 14. On day 28, spleen
cells were restimulated with UV inactivated HSV in vitro for 5 days, and harvested as
effector cells for CTL assays.

The spontaneous release of Cr^'from the target cells was less than 20%. CTL assays
were repeated two times. The data is representative of one of experiment. The specific
lysis shown in the table are correspondent to effector to responder ratio of 100:1.
Target cells infected with live HSV at m.o.i. = 5 four hours before CTL assay, and four
hours during the assay.

'' Target cells were pulsed with lOOug/million cells of ICP27 448-456(DYATLGVGV)
peptide.

Target cells were pulsed with lOOug/million cells of gB 493-505(SSIEFARL) peptide.
Target cells were transiently (48 hours) transfected with pcMini or pcDNAS.l
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Table 3-4 Cvtokine production induced by pcMini immunization
Cytokine(ng/ml)
Immunization ®

IFN-y

Restimulation''

IL-4

IL-2

BALB/c

C57BU6

BALB/c

C57BU6

BALB/c

APC/gDi.23

829 ±210

137144

87112

96124

21110

1416

UV irradiated HSV

35019

27015

110

Oil

3101217

101150

111

010

C57BU6
live HSV

pcMini

pcDNA3.1

APC/ gD,.23

2013

N/A

35112

N/A

N/A

010

010

111

713

111

010

010

010

N/A

N/A

010

010

UV irradiated HSV

2011

2011

APC/ gD 1.23

1216
1 10

UV irradiated HSV

N/A

4^

" Mice were injected i.m. with various immunogens on day 0 and day 14. On day 28, spleen cells were restimulated in
vitro for 5 days. The cell culture supernatant was assayed for cytokines by ELISA.

In one of the experiments, spleen cells were restimulated with gD peptide pulsed x-radiated APCs(R: S ratio at 50:1) In

another experiment, spleen cells were restimulated with UV irradiated HSV (m.o.i of 1.5) for 5 days. The samples were

pooled spleen cells in each group. The data represent the mean of the triplet samples + SD.In both the experiment, spleen
cells restimulated with ConA were served as a positive control. Cells without restimulation were used as negative control.

Fig. 3-1 pcMlni Construct

The minigene encoding a 51 amino acid peptide was inserted into Hind III and
BamH I restriction sites of pcDNAS.l expression vector plasmid. The sequences within

the boxes represent the immunogenic epitopes. Expression of the gene is under the
control of CMV early gene promoter.
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Fig. 3-2 Minigene expression
a.

mRNA expression of the minigene detected by RT-PCR using two internal

primers. The resulting PGR products from the minigene amplification are 170 bp. The
positive control was pcMini as the template. The lower faded bands represent the primers.
P-actin level in the RT samples were equivalent(not shown).

b.

Protein expression of the minigene detected by dot-blot. A. 10 ug of gD protein,
B. 293 cell lysate, C. pcMini-transfected 293 cell lysate, D. pcDNA3.1-transfected 293

cell lysate, E. pcMini-injected muscle cell lysate, F. pcDNA3.1-injected muscle cell
lysate.
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Fig. 3-3 Antigen-specific lymphoproliferation

a.

BALB/c and C57BL/6 mice were immunized with various immunogens on day 0

and day 14. Spleen cells from individual mice (responders) were assayed for

lymphoproliferation. The stimulator cells were gD 1.23 or HA 301-313 peptide-pulsed or UV
inactivated HSV-infected irradiated syngeneic APCs. The stimulation index shown in the

figure represents those from the responder to simulator ratio of 25:1.

b.

BALB/c mice were immunized with various immunogens on day 0. Thirty days

after, VgD was boosted to some of the primed mice. Individual spleen cells (responders)
were tested for lymphoproliferation 7 days post-boost. The stimulators included UV
inactivated VgD, Vaccinia virus-infected, or gD 1.23 peptide-pulsed irradiated syngeneic
APCs. Primed mice without VgD boosting were also tested for gD-specific

lymphoproliferation. The stimulation index shown in the figure represent those from the
responder to stimulator ratio of 25:1.
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Fig. 3-4 Protection against HSV-1.17 cutaneous challenge

Immunized mice(day 0, and day 14) were cutaneously challenged with 10ID50
HsV-1 strain 17 at day 28. Skin lesions were observed after the viral challenge.

Figure 3-4 reflects the lesion scores during days 7 to13 post-challenge. Open circle: live
HSV-1-KOS immunized mice; black circle: pcMini immunized mice; gray circle:

pcDNAB.l immunized mice. a. BALB/c mice; h. C57BL/6 mice
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Part IV

Co-administration of DNA Encoding GM-CSF Modulates the Immunity
Induced by DNA Vaccines:

A Mechanism Mediated by Enhanced Antigen Presentation
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Rationale and Objectives

Previous observations of the immune responses induced by DNA vaccination

using plasmid DNA encoding HSV-gB antigen showed both humoral and cellular
immune responses were elicited, and provided protection against low dose HSV-1
zosteriform challenge in mice. However, the efficacy of DNA immunization compared to
live HSV vaccination was inferior. Co-administration of DNA encoding GM-CSF, a

cytokine known to stimulate and activate antigen-presenting cells(APCs), has been used
to enhance the immune responses in DNA vaccinations against rabies virus. In this study,

experiments were designed to investigate the effects of GM-CSF DNA on the immune
induction following DNA immunization in an HSV murine system.
The objectives were;

1) to determine whether co-administration of GM-CSF DNA reduced the antigen dose
required for immune induction;

2)to compare the nature of immune responses with and without co-administration and,
3)to determine whether GM-CSF had local or systemic effects on immune induction.

Introduction

Successful induction of effective immune responses by immunization with

plasmid DNA encoding various antigens provides a novel vaccine approach against
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infectious diseases, tumors and autoimmune disorders 25' 5- 32_ Protection by DNA

vaccination has been achieved in several animal models, including influenza 25^ herpes

simplex virus(HSV)22,23^ rabies infections 35 in mice, HSV infection in guinea pigs 2,
influenza virus infection in ferrets ^ papillomavirus infection in rabbits ^0, and human
immunodeficiency virus(HIV)infection in non-human primates 3. However, at least in
HSV models,,levels of protection were inferior in comparison with immunization with
traditional attenuated agents 22. Therefore, searching for effective means of enhancing
the immunogenicity of plasmid DNA-encoding antigens has become an important
strategy for this novel vaccine approach.
The mechanisms of immune induction by DNA immunization have yet to be fully
understood. However, there is strong evidence that bone marrow-derived antigen-

presenting cells(AFC)facilitate the priming of naive T cells in vivo during intramuscular
immunization with plasmid DNA 2,8,17

an early study by Manickan et ah, enhanced

immune responses were obtained following immunization with dendritic cells(DC)
transfected with DNA encoding HSV antigen 21. The practical application of this

approach, however; is limited since it requires a complicated preparation procedure for
collecting large amounts of enriched DCs.

The idea of using granulocyte-macrophage colony stimulating factor(GM-CSF)to

enhance the immunogenicity of DNA vaccines during immune induction came from its
well-known biological function as an essential factor for maintaining the viability and

activity of cultured dendritic cells in vitro

30,33
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addition, GM-CSF has also been

shown to up-regulate the expression of co-stimulatory molecules, such as theB7 family,
on various cell surfaces, including DC,eosinophils, mast cells, and tumor cell lines'3-

31' 14,15 justifying its wide use in modulating immunogenicity

Direct delivery of DNA

encoding GM-CSF into animals was first explored by Xiang et al.. DNA encoding
murine GM-CSF was co-inoculated with a plasmid expressing a rabies viral antigen.

Enhanced antigen-specific immune responses correlating with enhanced protection

against rabies virus challenge in vaccinated animals was achieved 34. The proposed
mechanism of the protection was related to the ability of GM-CSF to induce the

differentiation of hematopoietic progenitors into professional APCs 24.
In this study, a similar approach to that used in Xiang's rabies model was applied
to intramuscular immunization with plasmid DNA encoding HSV-1 glycoprotein B.
Additional issues, such as whether co-administration would reduce the antigen dose

required for immune induction in DNA immunizations; whether the co-administration
would change the nature of the immune responses, and whether GM-CSF had local or

systemic effects on immune induction, were investigated. The data obtained from this
study may increase our understanding of the mechanisms involved in the initiation of
immological responses following DNA vaccination.
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Materials and Methods

Mice

Three to four week old female B ALB/c and C57BL/6 mice (Harlan Sprague-

Dawley,Indianapolis, Inc) were used. During the experimental procedures, the
investigators adhered to guidelines proposed by the Committee on the Care of Laboratory
Animal Resources, Commission of Life Sciences, National Research Council. The animal

facilities of the University of Tennessee are fully accredited by the American Association
for Accreditation of Laboratory Animal Care.

Virus

HSV-1 strain KOS and strain 17 were grown on Vero cell monolayers(ATCC

CCL81)and stored in aliquots at -80°C until used. Titers were determined by plaque
forming assays and expressed as plaque forming unit(pfu) per milliliter.

Plasmid DNA

A full-length cDNA of HSV-1(KOS)glycoprotein B was kindly provided by Dr.
Martin Muggeride of Wistar Institute, PA. A 3.7-kb HindQl - BamHl fragment

containing gB was subcloned into pcDNA I (Invitrogen, San Diego, CA)allowing
expression of gB from a CMV promoter(Fig 4-1). This clone,(pcgBDNA I), was
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transformed into E. coli stain MC106(Invitrogen) by the CaCl2 method and stored at 70°C in Lennox L Broth (Gibco, Gaithersburg, MD)with 0.1% glycerol.

Plasmid DNA encoding GM-CSF(pRJB-GM)and the intact vector(no GM-CSF

insert, pRJB-c) were obtained from Dr. H. Ertl of Wistar Institute, PA (Fig 4-2). The gene
expression was under the control of an RSV (Rons Sacoma Virus) promoter. These

plasmid DNAs were transformed into E. coli strain XL1-Blue (Stratagene, La Jolla, CA)
and stored at -70°C.

Plasmid pCMYp-expressing bacterial P-galactosidase (Fig. 4-3) was purchased
from Clonetech, Palo Alto, CA,and transformed into E. coli strain XL1-Blue (Stratagene,
La Jolla, CA), and stored at -70°C as described above.

Plasmids were purified from E. coli bv using Megaprep plasmid isolation columns

(Promega, Madison, WI)according to the manufacturer's protocol. The purity of DNA
was determined by OD260/OD280 ratio (ranged from 1.78-1.82), agarose gel

electrophoresis, and Limulus amebocyte lysate single tests(< 0.06 endotoxin unit per 100
ug of DNA)(Endosafe, Charleston, SC). The concentration of the plasmid DNA was
determined by a GeneQuant RNA/DNA calculator(Pharmacia Biotech, Piscataway, NJ).
The expression of gB was tested in vitro by cell transfection as described in Part

m.Briefly, the L929 cell line(ATCC,Rockville, MD)were transfected with pcgBDNA I
and labeled with a 1:10 dilution of the primary antibody, mouse anti-HSV gB mAb

(Goodwin Institute for Cancer Research Inc., Plantation, FL)followed by a 1:20 dilution
of the secondary antibody, FITC-conjugated goat anti-mouse IgG (Southern
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Biotechnology Association, Birmingham, AL)in PBS containing 1%BSA and 0.05%
sodium azide. The HSV-infected L929 cells and pcDNAI-transfected cells were used as

positive and negative controls, respectively. Cells were analyzed by FAGS (fluorescence
activated cell scanner, Becton-Dickinson, San Jose, CA)and FITC-labeled cells
constituted 40% of the transfected cell population.

Supematants from pRJB-GM-transfected 293 cells(ATCC,Rockville, MD)were
analyzed by ELISA using a pair of antibodies from Pharmingen (San Diego, CA). GMCSF was detected in the supernatant from 1 million transfected cells at as low a dilution
as 1:1600. The negative control(pRJB-c transfected cell supernatant) revealed no
detectable GM-CSF by the same ELISA procedures.

Expression of P-galactosidase was evaluated by in situ staining for P-gal activity
in transfected 293 cells. Cells were incubated with P-gal substrate(0.2% X-Gal,2mM

MgCL,5mM K4Fe(CN)6-3H20,5mM K3Fe(CN)6 in PBS)at 37° C for eight hours. 80100% of the pCMVp-transfected 293 cells were positive for P-galactosidase. No positive
staining cells were found in the pcDNAI-transfected cells.

Immunization of mice

Mice were immunized on days 0 and 7 with various does of DNA in the tibialis

muscle. Mice immunized similarly with 1x10^ pfu live HSV-1,strain KOS,served as the
positive control, while immuniztion with vector DNA alone served as the negative
control. In some experiments, intramuscular immunizations were given only once. In
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other experiments, a single dose of 100 ug chicken egg albumin(OVA)(Sigma, St.
Louis, MO)in Hanks Balanced Salt Solution (HBSS), or OVA mixed with either 50 ug of
GM-CSF DNA or vector DNA was given intramuscularly to the mice.

Antibody assays

On various days after immunization, semm was collected from each mouse and

analyzed for gB,HSV or OVA-specific IgG and its isotypes by standard ELISA. Briefly,
ELISA wells were coated with either 100 ul of purified gB protein (1 ug/ml)(kindly

supplied by Dr. Rae Lyn Burke, Chiron Corp., Oakland, CA), HSV-1 antigen (1:200
dilution)(Advanced Biotechnologies Inc. Columbia, MD),or with 2 ug/ml of OVA

protein (Sigma, St. Louis,MO)in carbonate buffer(40 mM of NaHCOs and 20mM of
Na2C03, pH=9.8). After ovemight incubation at 4°C, the plates were washed three times
in PBS containing 0.05% Tween 20(Sigma, St. Louis, MO), pH 7.2(PBST),and then

blocked using PBS with 3% dehydrated nonfat-milk for 2 hours at 37°C. Serially diluted
two-fold serum samples (in PBS)in 100 ul final volume were added to each well. Wells
coated with 1 ug/ml of goat anti-mouse IgG,IgGl and IgG2a(Southern Biotechnology

Associates, Birmingham, AL)were treated with serially diluted mouse IgG,IgGl,and

IgG2a(Southem Biotechnology Associates, Birmingham, AL)were used to set up the
standard cure. Plates were incubated 2 hours at 37°C. After three washes with PBST, 100

ul of HRP-conjugated goat anti-mouse IgG,IgGl, or IgG2a were added to each well and
incubated for 1 hour. After three PBST washes, 2-2-azino-bis, 3-ethylbenz-thiazoline-6150

sulfonic acid substrate(Sigma, St. Louis, MO)was added. OD405 was read on a Spectra
Max 340(Molecular Devices, Sunnyvale, CA)and the concentrations of serum antibodies
were determined from the standard curve.

Neutralization assay

Fifty microliters of heat-inactivated serum were added in serial dilution in a 96well, flat-bottom microtiter plate (Falcon, Oxnard, CA)To this, 50 ul of 200 pfu live

HSV-1 KOS were added, The plate was then sealed and incubated for 18 hours at 4° C.
Fifty microliters of Low-Tox rabbit complement(1/10 dilution) was then added to the

wells and the plates incubated at 37°C for one hour. Finally, 5 x 10^ viable Vero cells
were added (50 ul volume)to each well and incubated at 37° C for 5 days. The serum
dilution that neutralized 50% of the virus was determined as the neutralization liter.

HSV-specific proliferation assays

Three to five weeks after immunization, spleen cells from immunized mice were

CO- incubated in 96 well plates in 10% RPMI with 10% fetal bovine serum, and with xirradiated-UV-inactivated HSV-infected (m.o.i = 1.5) or uninfected stimulator cells

(syngenic mouse spleen cells) at various responderrstimulator(R:S) ratios. On the fourth

day, plates were pulsed with luCi/well[^H] thymidine, 18 hours later, cells were
harvested and thymidine release read using a beta scintillation counter (Inotech, Trace
96). Proliferation was expressed as a stimulation index using the following formula:
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cpm of responders plus infected stimulators

cpm of responders plus uninfected stimulators

Delaved-tvpe hvpersensitivitv(DTH)assays

Each mouse was injected with 20 ul of 10^ UV inactivated HSV-1 KOS (10^ pfu
before inactivation)in the right ear and the same volume of Vero cell extract in the left
ear. The thickness of the right and left ears of each mouse were measured with a screw

gauge meter (Oditest, H.C. Kroeplin GHBH,Germany), and recorded individually. The
thickness of each ear was measured Ih before injection, and at 24,48, and 72 hours after

injection. The unit of measurement was 10"^ mm.The mean ear thickness of each ear
from each group of animals was calculated, and the mean increase in thickness before and
48 hours after injections were compared between the various vaccinated groups.

Cvtokine assays

Immune splenocytes obtained from various immunized mice were processed to

single cell suspensions in RPMI 1640(Gibco, Gaithersburg, MD)containing 10% FBS,
100 mM L-glutamine, 100 lU/ml penicillin, and 100 ug/ml streptomycin. One milliliter of

such suspension containing 10^ cells was stimulated in vitro with 1.5 m.o.i of UVinactivated HSV-1 KOS. Similar numbers of cells were treated as unstimulated or

concanavalin A(ConA)stimulated (5 ug/10^ cells /ml)in 12-well culture plates. Plates
were incubated at 37°C for 72 hours. The supernatant was collected and assayed for IFN152

y, and IL-4 by ELISA. Briefly, ELISA plates were coated with 2 ug/ml of rat anti- mouse

IFN-y or IL-4(Pharmingen, San Diego, CA)in carbonate buffer at 4°C overnight. After
PBST washing and blocking with 3% non-fat milk in PBS,the plates were incubated with

duplicates of serially diluted samples (two-fold dilution, starting at 1:1) and standards
(two-fold dilution, recombinant mouse IFN-y starting at 100 ng/ml or recombinant

mouse IL-4 starting at 500 pg/ml) at 4°C overnight. After thorough washing, the detecting
antibodies (biotinylated rat anti-mouse IFN-y or rat anti-mouse IL-4,(Pharmingen, San
Diego, CA)diluted 1:2000 in PBS, were added to the plates followed by avidin-

peroxidase(Zymed,South San Francisco, CA)incubation. Color was developed by
adding 100 ul of ABTS substrate and the OD405 was read on a Spectra Max 340
(Molecular Devices, Sunnyvale, CA). The concentration of the cytokines in the
supernatant was determined from the standard curve.

Cvtotoxicity Assays

Spleen cells collected after immunization were restimulated in vitro with u.v.

HSV-1 KOS (m.o.i.=5)in limiting dilution assay(LDA)medium and incubated at 37°C

for 5 days. On the day of the assay, target cells, EMT-6(H-2'') and EL-4(H-2'') cells were
infected with an m.o.i of 5 with live HSV-1 KOS for 4 hours. The infected targets along

with uninfected target cells(mock controls) were labeled with ^'Cr for 90 minutes. The
effector cells were then mixed with lO'^ of labeled target cells at various ratios from 100:1
to 3.3:1 in a total volume of 200 ul. Cells were incubated in triplicate wells in 96-well-V153

bottom plates for 4 hours. One hundred microliters of the supernatant was taken for
measurement of the radioactivity. The specific lysis of target cells was expressed as
follows;

% specific lysis = experimental release-spontaneous release x 100
total release - spontaneous release

The radioactivity measured from the supernatant of labeled target cells treated with 5%
Triton-x was recorded as total release. The radioactivity measured from the supernatant of

labeled target cells without treatment was recorded as spontaneous release.

Viral challenge

Prior to challenge, the left flanks of subject mice were depilated using a hair

clipper (Oster Animal Hair Clipper, Milwaukee, WI)and a chemical depilator, Nair
(Carter-Wallace, Inc., New York, NY). Following depilation, the mice were anesthetized
using metofane (Pitman-Moore, Inc., Mondalein,IL) and a total of 20 cutaneous

scarifications were made in an approximately 4 mm^ area. To such scarifications, 10 ul of

1 X lO'^pfu, 5 X 10"^ pfu, 1 X 10^ pfu, or 5 X 10^ pfu of HSV-I stain 17 was added, and
gently massaged into the wound. Ix 10^ pfu HSV-1.17 caused skin lesions in 50% of the
infected BALB/c mice (ID50). Similarly, 5 x 10^ pfu HSV was the ID50 for C57BL/6
mice. Animals were inspected daily for the development of ipsilateral zosteriform

lesions, general behavioral changes, encephalitis, and mortality following challenge. The

severity of lesions were scored as follows: 1+ = vesicle formation; 2+ = local erosion and
ulceration of the local lesion; 3+ = mild to moderate ulceration, and 4+ = severe
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ulceration, hind limb paralysis, and encephalitis. Any moribund animals were
euthanatized.

B - galactosidase assays

Two days after intramuscular immunization with pCMVp,or pCMVP and pRJBGM,or pCMVp and pRJB-c, the mouse tibialis muscles were collected and homogenized
in 500 ul of radioimmunoprecipitation assay(RIPA)buffer containing 1% NP40, 1%
sodium deoxycholate, 1% Triton X-100, and 100 uM each of the protease inhibitors

(phenylmethylsulfonyl fluoride, aprotinin, and leupeptin). After centrifugation at 12,500

rpm for 20 minutes, supematants were incubated in 0.1 ml of 0.66 mg/ml O-nitrophenylp-D-galactopyranoside(ONPG)in a buffer containing lOOmM sodium phosphate, pH
7.3, ImM MgCla and 50mM p-mercaptoethanol at 37°C in 96-well ELISA plates.
Incubation was terminated when the supernatant changed color. The color change then

stopped by adding 50 ul of IM Na2C03 to each well. OD420 was then read by the

SpectraMax 340(Molecular Devices, Sunnyvale, CA). The protein concentration of the
supematants was determined by BCA protein assays according to the manufacturer's
protocol (Pierce, Rockford,IL). The specific activity was calculated by using the

following equation: SA (units/mg)=(OD420 x 380)/ time of incubation x protein
concentration.
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Results

Enhanced humoral immune responses by co-administration of GM-CSF DNA

To initially determine the dose of GM-CSF DNA for co-administraton, 100 ug of

pcgBDNAI was mixed with various amounts of pRJB-GM and injected intramuscularly
to BALB/c mice. A significant enhancement of antibody production was found in mice

receiving at least 50 ug of pRJB-GM co-administration (Fig. 4-4). Therefore, 50 ug of
pRJB-GM was chosen for further studies.

In early reports on intramuscular immunization with pcgBDNAI,the optimal dose
that induced significant immune responses in the majority(>80%)of the tested mice was

at least 90 ug DNA/mouse/injection

In order to find out whether co-administration of

GM-CSF DNA would reduce the antigen required in DNA vaccination, a comparison

study was employed using BALB/c mice injected intramuscularly injected with 10,50,
100, of 200 ug pcgBDNAI with or without co-administered GM-CSF DNA.. The gB-

specific antibodies in mice receiving co-administered GM-CSF were at least two-fold
higher than those in mice without GM-CSF co-administration, especially in groups
injected with lower amounts of pcgBDNAI(fig.4-5). With 10 ug pcgBDNA i.m.
immunization, only one out of four mice developed respectable antibody titers. However,

three out of four mice receiving 10 ug pcgBDNA mixed with 50 ug pRJB-GM produced

equivalent amounts of antibody in the group receiving 100 ug gB DNA.Similar antibody
levels also were seen in mice receiving 50 ug gB DNA i.m.
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Studies from other groups indicate that plasmid DNA encoding

immunostimulatory sequences (unmethylated CpG motifs) enhances antigen specific

immune responses, and in particular, promote a Thl-type response^^. In the case of
antibody stimulation, more IgG2a was found when bacterial DNA vector was coadministered with DNA encoding antigens I'The pRJB-GM which encodes murine GM-

CSF also contains CpG sequences that are primarily localized to the ampicillin resistance

gene of the plasmid. In order to identify the role of these CpG sequences in immune
modulation, pcgBDNAI was mixed with pRJB-c, the plasmid vector without the GMCSF cDNA insert, and injected intramuscularly to mice. Compared to immunization with

pcgBDNA alone, co-administration of pRJB-c did not significantly increase antibody
production. However,co-administration did diminish gB- specific IgGl in both BALB/c
and C57BL/6 mice (Table 4-1). In contrast, co-administration of pRJB-GM with

pcgBDNAI elevated antigen-specific IgG levels, including HSV-specific neutralizing
antibodies. More interestingly, the antigen-specific IgGl in GM-CSF co-administered

mice increased significantly compared to those immunized mice with gB DNA alone

(Table 4-1). These data indicte, since pRJB-GM and pRJB-c contain identical CpG

sequences, that the CpG sequences in the plasmid DNA did not contribute to the
enhancement of antibody induction during co-administration. Rather, it appeared that
GM-CSF did contrubite to antibody induction enhancement.
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Enhanced cellular immune responses by co-administration of GM-CSF DNA

After two doses of gB and GM-CSF DNA co-administration, cell mediated

immunity was measured using immune spleen cells in vitro assays, including antigen
specific lymphoproliferation, cytokine production, and MHC-restricted cytotoxic
activities. Compared to immunization with gB DNA alone, or with gB DNA mixed with
vector DNA, mice receiving co-administered gB and GM-CSF DNA developed superior

lymphoproliferation responses and produced more IL-4 upon restimulation with UVinactivated HSV-l.KOS (Fig. 4-6 and Table 4-2). The stimulation index increased 2-fold
in B ALB/c mice, and 4-fold in C57BL/6 mice. The differences in IL-4 production were

more significant. With gB DNA immunization, spleen cells produced very small amounts
of IL-4(not detectable in BALB/c mice and 0.04 ng/ml/million cells in C57BL/6 mice).

However,in gB and GM-CSF DNA co-immunized mice,IL-4 levels were increased to

2.51 ng/ml/million cells(BALB/c) and 0.72 ng/ml/million cells(C57BL/6). Table 4-2
represents one of two experiments. The increase in IL-4 production was seen in both
experiments, although the concentrations of the cytokine varied.

Effects of co-administration of GM-CSF DNA on HSV induced zosteriform lesion

The protective immunity to HSV was assessed by zosteriform challenge, which
has been demonstrated in early studies22.28 Protection can be readily induced following

i.m. immunization with pcgBDNAI to 10ID50 HSV-1.17 challenge(80% protection) in
both BALB/c and C57BL/6 strain of mice. However, at higher zone dosing (SO-SOOIDso),
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protection was reduced to less than 50%,as evidenced by the development of skin lesions
(Table 4-4). In mice receiving GM-CSF and gBDNA co-immunization, protection
increased to 100% in both the 10 and 50ID50 viral challenge groups. At 100ID50 dose,

70-78% of the mice remained resistant to skin lesion development. Injection of pRJB-GM

or pRJB-c alone did not provide protection. When mixtures of pRJB-c and pcgBDNAI
were co-injected, recipient mice were protected at levels similar to those mice receiving
gBDNA immunization alone.

Mechanisms involved in the immune modulation regulated by co-administration of
GM-CSF DNA

Stimulation and activation of dendritic cells and macrophages during immune

induction is the proposed mechanism mediating the enhanced response observed

following co-administration of GM-CSF DNA and gB DNA. Whether these activated
APCs actually increase antigen expression and/or presentation is not clear. To investigate
this, several experiments were performed. First, p-gal activity in muscle lysates was

measured and compared following injections with DNA encoding the p-galactosidase

gene alone, or with co-administered GM-CSF DNA. As shown in Table 4-5,the P-gal
activity was unchanged with or without GM-CSF DNA co-administration. Secondly, if
APCs are activated by GM-CSF locally within the muscle tissue to take up the DNA and

subsequently present the antigen, enhancement of immune responses would be expected
when GM-CSF DNA is administered prior to gBDNA injection at the same site.
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Unfortunately, neither antibody levels nor lymphoproliferation responses were enhanced
in mice given GM-CSF DNA two and four days prior to gBDNA immunization (Table 4-

6). Giving GM-CSF DNA after the administration of gBDNA or at a different injection
site also had no effect on the antibody and proliferation responses. Thirdly, if GM-CSF

DNA injection enhanced antigen presentation by APCs,co-administration of GM-CSF
DNA with a soluble protein antigen should increase immune induction. To test this

hypothesis,OVA protein mixed with GM-CSF DNA was co-injected intramuscularly to
mice. The immune responses generated were compared to those in mice immunized with
OVA alone or OVA mixed with vector DNA.Two weeks following immunization, mice

injected with OVA and GM-CSF DNA developed significantly higher antibodies against
OVA than those mice injected with OVA alone or OVA plus vector DNA (Table 4-7).
These data indicated that the immune modulation effects of co-administrered GM-CSF

are mediated by enhanced antigen presentation at the local site, rather than by enhanced
antigen expression in APCs.

Discussion

Respectable immune responses can be elicited by DNA vaccination in many

systems

However,few of these novel approaches achieved solid protection against

pathological challenge. One of the reasons lies in the poor efficacy of the DNA vaccine.
In this study, a DNA encoding murine GM-CSF cDNA was chosen to enhance the
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immune induction by co-administration with a plasmid encoding HSV-1 gB antigen. The
results demonstrated that co-administration of GM-CSF DNA not only augmented

antigen-specific B and helper T cell responses, but also promoted protection against
HSV-1 zosteriform infection. This modulation may be the result of activation of

professional APCs at the injection site by overexpressing the GM-CSF cytokine.
Intramuscular injection of plasmid DNA is convenient and can more readily

induce immunological responses compared to other DNA delivery methods such as
intradermal injection and particle bombardment 'k However,i.m. immunization

generally uses 100-fold more DNA than gene gun immunization to generate equivalent
antibody responses '2. Possible explanations include that gene gunsdirectly transfect
DNA to the cell cytoplasm,while skeletal muscle cells must take up DNA from the

extracellular space, a less efficient method. This study shows for the first time that
introduction of GM-CSF DNA together with HSV-gB DNA into mouse skeletal muscle
allows a 10-fold deduction in the dose of gB DNA to elicite the same antibody reponse

levels as with gB DNA given alone. This increased responsiveness to antigenic DNA

may result from both increased numbers and activity levels of APCs by GM-CSF

expression at the local site. When activated APCs accumulate at the inoculation site, two
mechanisms may account for the observed augmented immune induction. Firstly, more
extracellular DNA could be taken up by APCs and presented to the immune system.

Secondly, more APCs would encounter the antigen released from tissues damaged by

infiltrating cells at the injection site. The P-galactosidase activity in muscles injected with
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P'gal DNA alone was not significantly different from muscles co-injected with GM-CSF
DNA. Moreover,if the first assumption were responsible for the observed enhancement,

one would expect to detect a similar immune enhancement following injection of antigen

encoding DNA enriched with activated APCs. However, administering GM-CSF DNA
i.m. 2-4 days before injecting pcgBDNA neither increased antibody production nor
lymphoproliferative responses. Additionally, other groups have demonstrated that
encoded gene expression only occurrs in the injected muscle, not in draining lymph

nodes. Taken together, antigen presentation by direct uptake of DNA to APCs should not
be considered as a major contributor to immune induction after intramuscular
immunization, although experiments have shown in vitro transfected DCs both express

and present the antigen to the immune system 21. Currently, the cross-priming mechanism
of immune induction following DNA vaccination, in which antigen expressed by

myocytes are transferred to APCs for presentation, is supported by several studies n. It is
likely that GM-CSF enhances this pathway by ensuring a more efficient antigen

presentation. As evidence provided by this study demonstrates, co-administration of GMCSF DNA and OVA protein augments OVA-specific antibody responses. Another

possible mechanim of GM-CSF's action is to increase the expression of co-stimulatory
molecules on myocytes or other cell types thus transforming them to an APC. The IFN-y

induced by DNA CpG sequences may also play a role. To prove this, however, sensitive
quantitation analyses of surface molecules such as the B7 and ICAM-1 families have to
be developed. So far, then, this dilemma remains unsolved.
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Although CpG sequences in bacterial DNA have been found to stimulate Mtj) and
B cells in vitro and to enhance immune induction by DNA immunization by several

groups

the impact of this co-administration system is limited. Using pRJB-c vector

along with gBDNA to immunize mice neither promoted antibody production nor
proliferative responses, but did suppress IgGl and IL-4 production. In contrast, coadministration of GM-CSF increased both B and T helper cell responses and further, it
overcame the inhibitory function of CpG sequences within its DNA structure on IL-4 and

IgGl production. The mechanisms involved in these responses are not quite clear, but a
possibility might be that GM-CSF activated cells such as B cells and mast cells up-

regulate IL-4 expression

and the subsequent IgGl production 27. lL-4 and IgGl may

not represent the switch of Th type since ThI responses still dominanted in the coadministered animals. The co-administration of GM-CSF DNA did not augment DTK

and cytotoxic T lymphocyte activities, which left the higher titer of neutralizing antibody

as the major reason for enhanced protection against HSV-1 zosteriform challenge 29.
GM-CSF induced by DNA injection seemed to act only locally, since when GMCSF DNA co-injected at different sites with antigen DNA elicited no immune
enhancement. It is interesting to note that only injections with the mixed DNA

preparations of pRJB-GM and pcgBDNAI yielded the immune modulation. For unknown
reasons, prior to or after gBDNA intramuscular delivery, GM-CSF appeared to have no
effect.
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In conclusion, immune modulation of intramuscular immunization with plasmid

DNA encoding antigens could be achieved by co-administration of DNA expressing GMCSF. The advantages of this approach are: the enhancement of antibody production and T

helper cell proliferation; the reduction of required antigen DNA dose, and a lack of
alteration of the nature of the immune responses. Perhaps, this approach whould be more
useful in the situations where the encoding antigen induces a Th2-type response, since IL4 and IgGl production are enhanced.
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Table 4-1 gB-specific antibodies in immunized mice

litimunogen

OS
VO

gB + GM-CSF

gB

HSV

Antibodies

gB + Vector

Vector

BALB/c

C57BL/6

BALB/c

C57BL/6

BALB/c

C57BL/6

BALB/c

C57BL/6

BALB/c

C57BL/6

Neutr. Ab

1:64

1:128

1:8

1:16

1:32

1:32

1:16

1:16

<2

<2

Total IgG

48.7+2.9

54.6±1.8

21.8±2.2*

30.915.0#

36.911.8*

62.318.6#

25.413.3

26.816.4

<0.01

<0.01

IgG2a

12.5±3.3

20.0+3.0

8.0±3.5

23.511.6

7.312.8

31.214.6

9.912.7

20.112.1

<0.01

<0.01

IgGl

0.6+0.1

1.4±0.3

0.110.0**

0.310.1##

0.910.1**

7.611.6##

<0.01

<0.01

<0.01

<0.01

IgG2a:IgGl

21.5

14.9

132.7

81.1

8.5

4.1

>985

>201

-

-

® Three to four weeks old female BALB/c or C57BL/c mice were i.m. immunized with 10^ pfu HSV-l-KOS, 100 ug of

gBDNA, 100 ug of gBDNA + 50 ug of pRJB-GM, 100 ug of gDDNA + 50 ug of pRJB-c, or 100 ug pcDNAI + 50 ug of
pRJB-c on day 0 and day 7.

'' On day 20 ,sera samples were collected from individual mice(n=5)and assayed for gB specific antibodies by ELISA.
The concentration was expressed as the mean of 5 mice in each group (ug/ml)± SD. Equal volume of the individual sera

samples were pooled in each group and tested for neutralizing antibody titers.
*, **,#,##, concentrations were significantly different between gB and gB+GM-CSF groups by t-student test.

Table 4-2 Cvtokine profile in gB and GM-CSF DNA co-administered mice
cytokines"
IFN-v(ne/ml)

Immunogen®
HSV

GB DNA

GB + GM-CSF

GB + vector

Vector

IL-4(ng/ml)

BALB/c

C57BL/6

BALB/c

C57BL/6

HSV

48.6 ±4.3

52.1 ±3.6

0.12 ±0.03

0.14 ±0.04

ConA

86.0 + 5.6

76.0 ±4.2

0.86 ± 0.08

0.76 ± 0.08

None

1.4 + 1.0

<0.1

<0.01

<0.01

HSV

20.0 ±3.2

35.3 ±4.0

<0.01

0.04 ±0.01

ConA

85.0 ±7.2

69.2 ± 6.3

0.56 ± 0.02

0.65 ±0.02

None

<0.1

<0.1

<0.01

<0.01

HSV

22 ±1.6

32.1 ±4.4

2.51 ±0.10

0.72 ± 0.08

ConA

94.1 ±3.5

85.2 ±5.2

0.65 ± 0.02

0.77 ± 0.04
<0.01

Stimulation''

None

<0.1

<0.1

<0.01

HSV

35.5 ±3.7

30.2 ± 2.4

0.05 ± 0.01

<0.01

ConA

90.2 ±5.2

78.8 ±3.2

1.22 ±0.12

1.02 ±0.10

None

<0.1

<0.1

<0.01

<0.01

<0.01

<0.01

HSV

<0.1

<0.1

ConA

78.3 ±3.3

72.1 ±4.2

0.92 ± 0.05

0.83 ± 0.03

None

<0.1

<0.1

<0.01

<0.01

Three to four weeks old female BALB/c or C57BL/c mice were i.m. immunized with

10^ pfu HSV-l-KOS, 100 ug of gBDNA, 100 ug of gBDNA + 50 ug of pRJB-GM, 100
ug of gDDNA + 50 ug of pRJB-c, or 100 ug pcDNAI + 50 ug of pRJB-c on day 0 and 7.
Spleen cells from immunized mice were harvested on day 28. Pooled cell population
(n=5) were then restimulated with UV.inactivated HSV ,ConA,or without stimulation in
vitro for 72 hours.

The supernatant from the restimulated cell cultures was analyzed for IL-4 and IFN-g by
ELISA. The data represent one of the two experiments.
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Table 4-3 DTH reaction in the immunized mice

Increased ear thickness"
C57BL/6

BALB/c

Immunogen

Right(vero)

left(HSV)

right(vero)

left(HSV)

HSV

0.8 ± 0.8

14.0 ±2.5

0.8 ± 1.3

10.0 ± 1.9

gB

0.5 ± 0.5

7.5 ±2.4

1.3 ±0.8

5.8 ± 1.4

gB + GM

0.8 + 0.4

6.0 ±1.9

0.3 ±0.4

6.2 ±1.6

gB + vector

0.5 ± 0.9

7.0±1.8

0.8 ±0.4

6.0 ±2.8

Vectors

1.0 ±0.7

2.5 ±1.0

1.3 ±0.4

1.0 ±0.4

Mice immunized with immunogens on day 0 and day 7 were used for DTH assay on day

20. Twenty microliter of HSV-l-KOS (10® pfu before UV inactivation) or vero cell
extract were intradermal injected to the mice left and right ear respectively. Values are

expressed as mean (10"^ mm,n=4)± SD increase in ear thickness at 48 hours after viral
challenge.
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Table 4-4 Protection against HSV-1 zosteriform challenge"

HSV
Dose

gB

gB + GM-CSF

gB + vector

GM-CSF

vector

BALB/c C57BL/6
BALB/c C57BL/6 BALB/c C57BL/6 BALB/c C57BL/6 BALB/c C57BL/6 BALB/c C57BL/6

IOID50

20/20

5/5

16/20

4/5

20/20

5/5

4/5

5/5

1/5

1/5

0/20

0/20

50ID50

10/10

nd''

5/10

ND

10/10

ND

3/5

ND

0/5

ND

0/10

ND

100 ID50

15/15

15/15

9/20

3/5

14/20

4/5

2/5

3/5

0/5

0/5

0/20

0/10

500 ID50

9/9

ND

3/9

ND

5/9

ND

1/5

ND

0/5

ND

0/9

ND

" Three to four weeks old female mice were immunized on day 0 and day 7. Animals were challenged on day 20 with
different dose of HSV-1.17 and observed for 14 days. The number of animals that developed lesions out of the number
to

infected is shown in the table.

b.

ND,not done.

Table 4-5 B-gal activity in iniected muscle

Immunization"

p-gal specific activity''

pCMVp

67± 10

pCMVP + pRJB-GM

77 ±30

pCMVp + pRJB-c

57± 13

BALB/c mice were injected with 100 ug of pCMVp, 100 ug of pCMVp mixed with 50

ug pRJB-GM,or 100 ug of pCMVp mixed with 50 ug pRJB-c into tibialis muscle on day
0.

On day 2 after immunization, the tibialis muscle were collected and homogenized. The

supernatant of the lysate was assayed for p-gal specific activity. The data were expressed
as mean specific activity (units/mg protein)± SD (n = 4).
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Table 4-6 Co-administration and enhancement

IgG"

S.I.'

day 4

day 28

day 28

-

33.5 ± 57.9

1.7 ±0.5

Immunization''

day 2

day -4

day -2

day 0

GM

-

gB

-

gB

100.1+74.2

6.9 ± 3.4

GM

gB

271.4 ±347.1

3.4 ± 2.3

Vec

gB

1970.4 ± 388.4

5.0 ±0.5

1546.2 ± 506.5

5.5 ±1.2

gB+GM

4211.8 ±804.8

40.2± 15.7

gB+Vec

1228.8 ±152.4

6.0 ±2.0

Vec

"gBtr)
GM(1)

gB

GM

547.4 ±590.2

3.0 ± 1.8

gB

Vec

144.4 ±250.1

1.7 ± 1.0

gB

-

GM

334.5 ±579.3

2.5 ±1.7

gB

-

Vec

73.8 ± 87.4

2.0± 1.1

gB

-

1710.4 ±462.9

5.6 ± 1.0

-

Mice were i.m. injected with GM-CSF DNA or vector DNA 4 days or 2 days prior to

and after gB DNA injection. Individual mouse serum gB specific IgG and HSV specific

lymphoproliferation of spleen cells were measured 4 weeks after the inoculation.
Antibody concentration was expressed as mean (ng/ml) ± SD,(n=4)

Stimulation index was expressed as mean ± SD,(n=4)

pcgBDNAI was injected into the right tibialis muscle, and pRJB-GM was injected into
the left tibialis muscle.
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Table 4-7 OVA-specific antibody response

Immunization"

ova IgG (ng/ml)''

OVA

1567 ± 300

OVA + pRJB-GM

2634 ± 433

1506 ± 89

OVA + pRJB-c

BALB/c mice were i.m. immunized with lOOug of OVA protein in HBSS, 100 ug ova

protein mixed with 50 ug pRJB-GM,or 100 ug OVA mixed with 50 ug pRJB-c on day 0.
On day 14 after immunization, sera samples were collected from individual mouse and
analyzed for OVA-specific antibody response by ELISA. The data were expressed as the
mean of antibody concentration ± SD (n=4).

Values are significantly higher than other two groups (student t-test p<0.01).
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Fig. 4-1A map of pcgB DNA

The pcgBDNAI was desinged to express HSV-1 KOS glycoprotein B (gB)from
the human cytomegalovirus(CMV)immediate early gene promoter. It contains the
immediate early gene promoter/enhancer from CMV,an intron (splice donor/splice

acceptor) and polyadenylation signal from SV40,and the full-length gB cDNA inserted
into Hind DI and BamH I restriction enzyme sites of the multiple cloning sites of
pcDNAl.l.
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Fig. 4-2 A map of pRJB-GM

The pRJB-GM contains the murine GM-CSF cDNA flanked by the Rons sarcoma

virus promoter(Rous LTR)and bovine growth hormone polyadenylation signal

(BGHpA)at Hind III and Xba I sites. The SV40 vims replicative origin(SV40 Ori)
allows replication of the plasmid in cell lines transformed with SV40 T large antigen.
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I
Hindlll

Fig. 4-3 A map of pCMVp

pCMVP is a mammalian reporter vector desinged to express p-galactosidase from
the human CMV immediate early gene promoter. pCMVp contains the immediate early

gene promoter/enhancer from CMV,an intro and polyadenylation signal from SV40, and
the full-length E.coli P-galactosidase gene with eukaryotic translation initition signals.
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Fig. 4-4 Dose of GM-CSF DNA on antibody production

Amixtureof lOOugofpcgBDNAIandOug, 10 ug, 50 ug, 100 ug ,or 200 ug

pRJB-GM in a total volume of 100 ul in HBSS were injected into tibialis muscles of
BALB/c mice. Six weeks after the immunization, sera samples were collected from mice

and analyzed for gB specific IgG and isotypes by ELISA."r" stands for IgG2a to IgGl
ratio. Error bars stand for standard deviation of the mean antibody concentration in each

group. IgG2a to IgGl ratio changed significantly (p<0.01) between co-administration of
50 ug pRJB-GM and without co-administration or with 10 ug pRJB-GM coadministration, and between co-daministration of 200 ug of pRJB-GM and without coadministration or with 10 ug pRJB-GM co-administration.
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Fig. 4-5 GM-CSF DNA on antigen dose required for antibody production

BALB/c mice were i.m. immunized with 50 ug pRJB-GM mixed with 10 ug, 50

ug, 100 ug, or 200 ug of pcgBDNAI in 100 ul of HBSS. Six weeks after immunization,
the sera samples were collected from each mouse and assayed for gB specific IgG by
ELISA. The mean values of antibody concentration were compared between with GMCSF co-administration and without co-administration groups by student t-test. The p
values were given for the each comparison.
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Fig.4-6 HSV-specific lymphoproliferation of immune splenocytes

BALB/c and C57BL/6 mice were i.m. immunized with 10® pfu live HSV, ICQ ug

pcgBDNAI, lOOug pcgBDNAI mixed with 50 ug pRJB-GM, 100 ug pcgBDNAI mixed
with 50 ug pRJB-c, orlOO ug pcDNAI mixed with 50 ug pRJB-c on day 0 and day 7. Five
weeks after immunization, spleen cells from immunized mice were stimulated with UV
inactivated HSV-1 KOS infected syngenic APC in vitro and assayed for

lymphoproliferative responses. The data in the figure represent one of the three
experiments.

186

Stimulation Index
I-*

O

ts>

4^

9\

(Xi

OK>

iUO\

I-*

NJ

aoO

HSV
oo

oo

gB+GM

gB+vector
n
Ul

ij}

vector

03
r
0\

w

Fig. 4-7 HSV-specific cytotoxic activities

a.

-v6

BALB/c mice were i.m. immunized with 10 pfu live HSV, 100 ug pcgBDNAI,

100 ug pcgBDNAI mixed with 50 ug pRJB-GM, 100 ug pcgBDNAI mixed with 50 ug

pRJB-c, or 100 ug pcDNAI mixed with 50 ug pRJB-c on day 0 and day 7. Five weeks
after immunization, the spleen cells from the immunized mice were restimulated in vitro
with UV inactivated HSV-1. KOS for 5 days and assayed for HSV specific cytotoxicity.

The figure represents the specific lysis of HSV infected EMT-6(H-2'') cells. The
spontanous releases of the assay were less than 20%. Lysis of allogenic target cells and
mock targets were less than 5%.

b.

C57BL/6 mice were i.m immunized with 10® pfu live HSV, 100 ug pcgBDNAI,

100 ug pcgBDNAI mixed with 50 ug pRJB-GM, 100 ug pcgBDNAI mixed with 50 ug

pRJB-c, or 100 ug pcDNAI mixed with 50 ug pRJB-c on day 0 and day 7. Five weeks
after immunization, the spleen cells from the immunized mice were restimulated in vitro
with UV inactivated HSV-1. KOS for 5 days and assayed for HSV specific cytotoxicity.

The figure represents the specific lysis of HSV-infected EL-4(H-2®) cells. The
spontanous releases of the assay were less than 20%. Lysis of allogenic target cells and
mock targets were less than 5%.
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Part V

Conclusions and Perspectives
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That cytokines function as important components of the immune system is
evidenced by their involvement in mediating immune responses against various

pathogens. In previous decades, the study of the roles played by cytokine in host defense
were difficult because of limitations in available technology. Recent developments in

molecular biology allow one to manipulate cytokine expression not only at the protein

level, but perhaps more usefully, at the gene level. One of the studies presented in this

dissertation appears to be the first study that analyzed the role of IFN-y in cutaneous HSV
infection using the gene knock out animal. The results reveal that IFN-y plays an

important role in the innate defense mechanisms against HSV infection. However, with
regard to specific immunity, compensatory pathways are able to overcome the lack of
IFN-y function. One of the possible pathways which is independent of IFN-y is likely
TNF-a since these two cytokines share many common functions. So far, no evidence has

been provided to prove this hypotheses. A useful approach might be the use of mice
which both cytokine genes have been knocked out, or single knock out animal combined
with mAb to neutralize cytokine in vivo. In addition, new technology which could better

control transgene expression during different stages of development will also be helpful
in the understanding of the importance of a chosen cytokine.

The second study in this dissertation deals with vaccination against HSV. With
the new discovery of in vivo expression of plasmid genes encoding proteins, DNA
vaccines are now being widely applied in many disease models. In the HSV model, at
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least three antigens(gB,ICP27, and gD)have been encoded by different DNA plasmids
12 3

and shown to induce both humoral and cellular immune responses in mice '' . My

study took advantage of genetic engineering technology to produce a minigene cassette

encoding three epitopes from gB,ICP27, and gD antigen of HSV.Immunization with this
minigene construct successfully induces epitopes specific CTL,lymphoproliferation, and
antibody responses. It is the first time plasmid DNA encoding multiple epitope peptide
was shown to elicit immune responses against a viral infection in mice. Although the

protective effects of the minigene immunization is less powerful than the conventional
vaccine, this technique provides a new opportunity for tailoring immunity using DNA
vaccination.

The last investigation reported in this dissertation is to modulate the immune
induction in DNA immunization by activating antigen presenting cells. The efficacy of

DNA vaccines may largely be determined by the immune induction phase. The
mechanisms involved, however, are as yet unclear. Strong evidence suggests that bone

marrow-derived antigen-presenting cells facilitate the process. Therefore, coadministration of GM-CSF DNA was chosen to target these antigen-presenting cells.

Both antibody and helper T cell response were enhanced with co-administration of the
cytokine and plasmid DNA encoding gB antigen. Co-administration of GM-CSF DNA

not only boosts the efficacy of the DNA vaccine against HSV,but also implicates its
potential as an adjuvant for other vaccines. In this study, GM-CSF was shown to act only
at local sites. This localized action of GM-CSF may not represent other cytokine's
192

activity when they are administered in a DNA form. Indeed, recent studies have indicated
that in vivo activation and stimulation of DCs by GM-CSF may not be as efficient as what
45

occurs in vitro. A better candidate for activating DCs in vivo is Flt-3 ligand ' . It would

be interesting to further investigate the effects of this cytokine in modulating the immune
induction during DNA vaccination.
In the past four and one half years, rapid progress has been made in the research
are in which I have been involved. Certainly, the data presented in this dissertation may

neither provide a comprehensive understanding of immunity against cutaneous HSV
infection nor resolve all issues in vaccine development against HSV. However,I hope

these studies have contributed in part to understand HSV vaccinology to indicate trends
which merit further investigation.
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